Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
09/2009 | Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions September class, title,number 09/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
09/24/2009 > patent applications in patent subcategories. class, title,number

20090239782 - High-molecular weight conjugate of resorcinol derivatives: Provided is a high-molecular weight conjugate of resorcinol derivatives which is excellent in water solubility and stability and has high antitumor activity even when used in a smaller total drug amount than the resorcinol derivatives. The high-molecular weight conjugate of resorcinol derivatives comprises a structure in which a carboxyl group... Agent: Nields, Lemack & Frame, LLC

20090239783 - Synergistic effects of combined administration of mirtazapine and a stimulant compound: The invention discloses combination therapies and formulations of a stimulant (e.g., amphetamine) and mirtazapine and their methods of use.... Agent: Darby & Darby P.C.

20090239784 - Stablised insulin compositions: The present invention relates to human insulin analogues having a fast onset of action. These analogues may have amino acid in position B26 substituted with Phe, or be Des(B30) analogues of human insulin. The invention also relates to compositions comprising such insulin analogues, and to compositions comprising a mixture of... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090239785 - Insulin derivative: The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to methods of providing such derivatives, to pharmaceutical compositions containing them, to methods of treating diabetes and hyperglycaemia using the insulin derivatives of... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090239786 - Novel biomaterial drug delivery and surface modification compositions: An antimicrobial coating is provided for use on textiles, medical devices, packaging materials, and the like.... Agent: Tyco Healthcare Group Lp

20090239789 - Methods of treatment with drug loaded polymeric materials: Polymeric microparticles have been developed which encapsulate therapeutic compounds such as drugs, cellular materials or components, and antigens, and can have targeting ligands directly bound to the microparticle surface. Preferred applications include use in tissue engineering matrices, wound dressings, bone repair or regeneration materials, and other applications where the microparticles... Agent: Pabst Patent Group LLP

20090239790 - Novel recombinant proteins with n-terminal free thiol: where EPO is an erythropoeitin moiety selected from erythropoietin or an erythropoietin variant having at least one amino acid different from the wild-type human EPO, or any pharmaceutical acceptable derivatives thereof having biological properties of causing bone marrow cells to increase production of red blood cells; cys represents the amino... Agent: Philip S. Johnson Johnson & Johnson

20090239788 - Recombinant or transgenic factor vii compound having a majority of glycan, biantennary, bisialylated and non-fucosylated forms: The present invention concerns a recombinant or transgenic factor VII compound, each factor VII molecule of the compound having glycan forms linked to N-glycosylation sites, wherein among all the factor VII molecules in said compound, glycan, biantennary, bisialylated and non-fucosylated forms are in the majority. The invention also concerns such... Agent: Marsh, Fischmann & Breyfogle LLP

20090239787 - Self-foaming cement for void filling and/or delivery systems: A self-foaming bone cement is described herein. In one variation, the bone cements include a self setting calcium phosphate cement formulation which when cured, forms macroscopic pores of varying sizes and densities with sufficient surface area to provide substantial regions for bone turnover.... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090239791 - Pharmaceutical composition containing lipophilic substance which inhibits il-2 production: A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can... Agent: Leydig Voit & Mayer, Ltd

20090239792 - Short fatty acid tail polymyxin derivatives and uses thereof: The present invention relates to a polymyxin derivative wherein the derivative has a total of three positive charges at physiological pH and wherein the terminal moiety (D) of the derivative comprises a total of 1 to 5 carbon atoms; and to a combination product comprising at least two such derivatives.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090239803 - Bite-size carbohydrate nutritional products and methods for using same: Bite-size carbohydrate-based products and methods of using same are provided. In a general embodiment, the present disclosure provides a bite-size carbohydrate-based product comprises a carbohydrate source comprising a glucogenic:fructogenic carbohydrate ratio ranging between about 1.5 to about 2.5 with at least 60% of the energy content of the bite-size carbohydrate-based... Agent: K&l Gates LLP

20090239800 - Clc channel ligand: Compositions and methods of using scorpion venom peptide that is a ligand for ClC channels are provided. One aspect provides a pharmaceutical composition containing an amount of GaTx2 effective to inhibit ClC activity. Methods of treating a disorder or symptom of a disorder related to aberrant ClC channel activity are... Agent: Pabst Patent Group LLP

20090239798 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.... Agent: Kaplan Gilman & Pergament LLP

20090239795 - Exendin fusion proteins: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to... Agent: Pharmacia & Upjohn

20090239794 - Hcv f protein and uses thereof: The invention provides polypeptides, nucleic acids, antibodies, compositions, vaccines, microarrays and uses thereof for the prevention, treatment of HCV infection. The invention further provides uses of the above-noted products for the detection and diagnosis of HCV infection. The invention further provides corresponding methods and commercial packages relating to such uses.... Agent: Fulbright & Jaworski L.L.P.

20090239802 - Hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof: The present invention relates to an immunostimulatory peptide derived from an Hsp70 protein and peptides comprising said immunostimulatory peptide. Furthermore the present invention pertains to polynucleotides encoding said peptide, vectors comprising said polynucleotides, fusion (poly)peptides comprising said peptide and compositions comprising said peptide. In addition the present invention relates to... Agent: Casimir Jones, S.c.

20090239796 - Methods for treating diabetes and reducing body weight: Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090239801 - Modified fusion polypeptides: Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains.... Agent: Crowell & Moring LLP Intellectual Property Group

20090239799 - Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation: A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090239793 - Polynucleotides and polypeptides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover: The invention relates to polypeptides and polynucleotides associated with trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, and uses of same in the prevention, diagnosis and treatment of conditions requiring regulation of trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover. In particular aspects, diagnostic methods are... Agent: Howson & Howson LLP

20090239804 - Prevention and treatment of osteoarthritis: Subjects lacking Nfat1 display osteoarthritis in weight-bearing joints. Osteoarthritic changes associated with Nfat1 deficiency are characterized by articular cartilage degradation, articular chondrocyte proliferation/clustering, progressive articular surface destruction, periarticular chondro-osteophyte formation, and exposure of thickened subchondral bone. Methods of treating osteoarthritis, methods of diagnosis and early prediction of the onset of... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090239797 - Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses: A non-human trangenic mammalian animal, as described above, contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises cis-acting regulatory units operably linked to a DNA sequence encoding human FIX protein without the benefit of the presence of a complete milk gene sequence... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090239805 - Human 3 relaxin: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment... Agent: Merchant & Gould PC

20090239806 - Glypican-3 (gpc3)-derived tumor rejection antigenic peptides useful for hla-a2-positive patients and pharmaceutical comprising the same: (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.... Agent: Greenblum & Bernstein, P.L.C

20090239808 - Calcium receptor activator: A calcium receptor activator and compositions containing at least one of the following: γ-Glu-Cys-Gly, γ-Glu-Cys(SNO)-Gly, γ-Glu-Ala, γ-Glu-Gly, γ-Glu-Cys, γ-Glu-Met, γ-Glu-Thr, γ-Glu-Val, γ-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, D-Cys, γ-Glu-Met(O), γ-Glu-Val-Val, γ-Glu-Val-Glu, γ-Glu-Val-Lys, γ-Glu-γ-Glu-Val, γ-Glu-Val-NH2, γ-Glu-Val-ol, γ-Glu-Ser, γ-Glu-Tau, γ-Glu-Cys(S-Me)(O), γ-Glu-Leu, γ-Glu-Ile, γ-Glu-t-Leu, γ-Glu-Cys(S-allyl)-Gly, γ-Glu-Gly-Gly, γ-Glu-Val-Phe, γ-Glu-Val-Ser, γ-Glu-Val-Pro, γ-Glu-Val-Arg, γ-Glu-Val-Asp, γ-Glu-Val-Met,... Agent: Cermak & Kenealy LLP Acs LLC

20090239807 - Methods and kits for diagnosing and/or assessing severity and treating gaucher disease: Methods and kits for treating Gaucher disease are provided. The methods are based on using agents capable of inhibiting proteasomal degradation of glucocerebrosidase and/or elevating a level of mis-folded yet active glucocerebrosidase in cell lysosomes. Also provided are methods and kits for diagnosing and/or assessing a severity and determining prognosis... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090239809 - Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.... Agent: Connolly Bove Lodge & Hutz, LLP

20090239810 - Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase: The present invention relates to piperidine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090239811 - Polycationic compounds and uses thereof: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally,... Agent: Pepper Hamilton LLP

20090239812 - Use of c7 sugars in prevention and treatment of mycoses: The object of the invention is use of at least one C7 sugar to make a composition intended for prevention and/or treatment of mycoses selected from among the group constituted of candidoses and pityrosporoses. The C7 sugars are preferably a water soluble extract of avocado sugars.... Agent: Foley And Lardner LLP Suite 500

20090239813 - Analogs of alpha galactosyceramide and uses thereof: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C′ channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A′ channel of human CDId, such that R1 fills at least at least 30% of the occupied volume... Agent: Fulbright & Jaworski, LLP

20090239814 - Carbohydrate conjugates as delivery agents for oligonucleotides: e

20090239816 - Multitargeting interfering rnas and methods of their use and design: Interfering RNA molecules are now designed and produced with specificity for multiple binding sequences present in distinct genetic contexts in one or more pre-selected target RNA molecules and are used to modulate expression of the target sequences. Such a multitargeting interfering RNA approach provides a powerful tool for gene regulation.... Agent: Crowell & Moring LLP Intellectual Property Group

20090239815 - Novel human micrornas associated with cancer: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.... Agent: Clark & Elbing LLP

20090239934 - Anti-myosin va sirna and skin depigmentation: The present invention relates to novel isolated siRNAs comprising a sense RNA strand and a complementary antisense RNA strand which together form an RNA duplex, characterized in that the sense RNA strand comprises a sequence which has at most one nucleotide that is distinct in relation to a fragment of... Agent: Birch Stewart Kolasch & Birch

20090239932 - Antisense oligonucleotides against protein kinase isoforms alpha, beta and gamma: Antisense compounds are provided for inhibiting PKB (protein kinase B) alpha, beta and gamma. The antisense compounds display high potency and selectivity. The antisense compounds do not suffer from problems of dimerisation or self-hybridization and have also been selected to not affect other enzymes. The antisense compounds may be used... Agent: Nixon & Vanderhye, PC

20090239933 - Hepatitis c antivirals: The present invention relates to deoxyribozymes targeting and cleaving HCV RNA. More particularly, the present invention relates to deoxyribozymes and composition used for the inhibition of HCV replication and HCV-related diseases.... Agent: Choate, Hall & Stewart LLP

20090239936 - Prophylactic and therapeutic agent for cancer: A Ras, Raf, MEK, ERK or RSK inhibitor, namely a P-glycoprotein expression inhibitor or a BCRP expression inhibitor, can be screened by utilizing the MAPK signaling activity as an indicator. It becomes possible to provide an anticancer agent which is reduced in resistance acquisition, and also provide an agent for... Agent: Foley And Lardner LLP Suite 500

20090239931 - Rna interference mediated inhibition of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20090239935 - Rna-helicase as a marker for rare tumors: Method for the diagnosis of diseases in a mammal, preferably in a human, wherein a probe from the mammal is examined with a view to an elevated level of RNA helicase and the elevated level of RNA helicase indicates the disease. The disease refers to esophagus carcinoma, pancreas carcinoma, stomach... Agent: Henry M Feiereisen, LLC Henry M Feiereisen

20090239937 - Apoptosis-inducing genes for treating cancer: The invention provides materials and methods related to the use of recombinant nucleic acid molecules containing an expression control element of an inhibitor of apoptosis protein (IAP) gene operatively linked to a coding region for an active cytotoxic/cytolytic agent. The recombinant molecules are used in methods to treat a variety... Agent: Marshall, Gerstein & Borun LLP

20090239939 - Combinations for introducing nucleic acids into cells: Combinations of a carrier and a complex consisting of a nucleic acid molecule and a copolymer are described, wherein the copolymer consists of an amphiphilic polymer, preferably polyethylene glycol, and a charged effector molecule, in particular a peptide or peptide derivative, as well as their use for the transfer of... Agent: Ropes & Gray LLP

20090239938 - Preventive/remedy for arteriosclerosis: According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090239940 - Treating heart failure and ventricular arrhythmias: The present invention provides methods and materials for treating heart disorders, including heart failure and arrhythmia, by enhancing SERCA2a activity. Heart cells in a subject can be treated, for example, by introducing, into the heart of the subject, an adeno-associated virus subtype 6 (AAV6) viral delivery system that includes a... Agent: Edwards Angell Palmer & Dodge LLP

20090239817 - Organic thiophosphate antiretroviral agents: A method for the prevention or treatment of human immunodeficiency virus infection by administering an effective amount of amifostine, phosphonol, or similar compound to an individual in need is provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090239818 - Effective treatment of ovarian cancer using triciribine and related compounds: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a... Agent: Morgan Lewis & Bockius LLP

20090239820 - Compounds and methods for treatment of solid tumors: The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that... Agent: Donald L. Barbeau

20090239821 - Destruction of microbial products by enzymatic digestion: Methods of treating a dialysis component by providing a dialysis component and contacting the dialysis component with an enzyme are provided. The enzyme breaks down microbial contaminants in the dialysis component. The enzyme may be separated from the dialysis component to provide a purified dialysis component. The purified dialysis component... Agent: K&l Gates LLP

20090239819 - Peritoneal dialysis solution test method: A method of testing a glucose polymer or a glucose polymer derivative includes providing a sample of the glucose polymer or glucose polymer derivative. The sample is filtered at a specified molecular weight cutoff to obtain a retentate portion and a filtrate portion. The retentate portion is added to a... Agent: K&l Gates LLP

20090239822 - Process for the preparation of esters of diacerein with hyaluronic acid and pharmaceutical compositions containing such esters: A process is described for the preparation of esters of diacerein with hyaluronic acid by means of which stable products are obtained, which are practically free of impurities and characterized by a prolonged anti-inflammatory activity. Also described are pharmaceutical compositions containing said esters having prolonged anti-inflammatory activity and are suitable... Agent: Michael G. Gilman

20090239823 - Foods and drinks having health benefits and method for adding health benefits to foods and drinks: A method for controlling intestinal function, blood sugar level, body fat or serum lipid, or maintaining and improving glucose tolerance. The method comprises giving to human body or animal foods and drinks, having health benefits, or enriched with health benefits, wherein the foods and drinks comprise as an active ingredient... Agent: Sughrue Mion, PLLC

20090239824 - Hydrolytically-resistant boron-containing therapeutics and methods of use: Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090239825 - Multi-carotenoids compositions and uses therefor: Methods for ameliorating the effects of benign prostate hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene,... Agent: Fasken Martineau Dumoulin, LLP

20090239826 - Compositions and methods for the regulation of homocysteine levels within the body: Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that reduce the production of homocysteine and either re-methylate homocysteine back to S-adenosylmethionine, or facilitate its conversion downstream to cystathione. The method of the invention... Agent: Seyfarth Shaw LLP

20090239827 - Compounds having lipid lowering properties: There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents.... Agent: Fish & Richardson PC

20090239828 - Adhesive preparation: The present invention provides an adhesive preparation having a plaster layer disposed on a support, the adhesive preparation comprising at least one active ingredient selected from the group consisting of a bisphosphonic acid derivative, its salt thereof and a hydrate of either of the bisphosphonic acid derivative or the salt,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090239829 - Thioaryl substituted inhibitors of zinc proteases and their use: There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R1, R2, n and ZBG have the meanings reported in the description useful, in therapy, as inhibitors of zinc metalloproteinases.... Agent: Bracco Research Usa Inc.

20090239830 - Treatment of viral infections by modulation of host cell metabolic pathways: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected... Agent: Pepper Hamilton LLP

20090239831 - Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis: The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as... Agent: Henry D. Coleman

20090239832 - Drugs for chronic pain: e

20090239833 - Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application: wherein R is H or C1-C4 alkyl; Z1 is carbonyl or β-hydroxymethylene; X1 is —O— or —S—; R5 is —OH, —OR6, —OCOOR6 or —OCOR7 wherein R6 is C1-C4 alkyl and R7 is C1-C4 alkyl, fluoromethyl or chloromethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated... Agent: Buchanan, Ingersoll & Rooney PC

20090239834 - Mcc-257 modulation of neurogenesis: The disclosure provides methods and a composition for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of (5-acetamido-N-(5alpha-cholestan-3alpha-yl)-3,5-dideoxy-2-O-methyl-D-glycero-alpha-D-galacto-non-2-ulopyranosonamide(MCC-257). The disclosure also includes methods and a composition for stimulating or activating the formation of new nerve cells based on the application... Agent: Dla Piper LLP (us)

20090239836 - Multifunctional ophthalmic compositions: An multifunctional ophthalmic composition includes a nonionic oxygen-containing polymer and a surfactant. The composition can be used to treat or control ophthalmic diseases, conditions, or disorders. The composition can be a drug delivery vehicle for medicaments having low solubility in water.... Agent: Bausch & Lomb Incorporated

20090239835 - Stabilization of glucocorticoid esters with acids: The invention relates to nonaqueous pharmaceutical preparations comprising a glucocorticoid ester and an acid, and to the stabilization of glucocorticoid esters in such preparations by acids.... Agent: Bayer Healthcare LLC

20090239837 - Cholesterol-producing yeast strains and uses thereof: The invention concerns the production of cholesterol in organisms of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090239838 - Pyrrolotriazine kinase inhibitors: e

20090239839 - Receptor antagonist: [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each... Agent: Sughrue Mion, PLLC

20090239840 - Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders: Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.... Agent: Knobbe Martens Olson & Bear LLP

20090239841 - Diaryl ureas as cb1 antagonists: Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including... Agent: Neurogen Corporation

20090239842 - Solutions containing epinastin: Topically administered aqueous solutions containing epinastin, optionally in the form of its racemate or its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090239844 - Ace inhibitor-vasopressin antagonist combinations: Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090239843 - Bridged diazepan orexin receptor antagonists: The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20090239845 - Pyrazole compounds as prostaglandin receptors ligands: Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R1, R2a, R2b, R10, R11 and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090239846 - Novel compounds: Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090239848 - Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090239847 - Organic compounds: e

20090239849 - Aryl-fused spirocyclic compounds: The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention... Agent: Merck And Co., Inc

20090239850 - Kinase protein binding inhibitors: The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20090239851 - Benzothiazinone derivatives and their use as antibacterial agents: e

20090239852 - Use of oxicam compounds: Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid... Agent: Fulbright & Jaworski L.L.P.

20090239853 - Fused heterocycle derivative: (wherein R1 represents optionally substituted lower alkyl, or the like; R2 represents an optionally substituted aliphatic heterocyclic group, or the like; R3 represents —C(=Z)NR5R6 (wherein R5 and R6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090239854 - Tetracyclic compounds: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the... Agent: Morrison & Foerster LLP

20090239855 - Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders: i

20090239856 - Use of pyrrolopyridine compounds for activating ppar receptors and treatment of conditions involving such receptors:

20090239857 - Triamine derivative: wherein R1 and R2 each independently represent a hydrogen atom, a hydroxy group, an alkyl group or an alkoxy group; Q1 represents a saturated or unsaturated bicyclic or tricyclic fused hydrocarbon group which may be substituted, a saturated or unsaturated bicyclic or tricyclic fused heterocyclic group which may be substituted,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090239858 - Therapeutic amides: e

20090239859 - Protein kinase modulators: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part... Agent: Morrison & Foerster LLP

20090239860 - Novel benzofuran derivative, medicinal composition containing the same, and uses of these: or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, arylalkenyl, aryloxy-lower alkyl, heteroaryl, heteroaryl-lower alkyl, etc; R3, R4, R5 and R6 are each hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, lower alkoxy, hydroxy, aryl, etc; provided that... Agent: Sughrue Mion, PLLC

20090239861 - Quinazoline derivatives as anticancer agents:

20090239863 - 1-aryl-or 1- alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20090239862 - Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators: Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1, such as obesity, and diabetes.... Agent: Merck And Co., Inc

20090239864 - 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors: wherein R1 represents a C1-C12 alkyl; R2 represents a hydrogen atom or the like; R3 represents a halogen or the like; q represents an integer of 1 to 7; R4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R5 represents a C6-C10... Agent: Greenblum & Bernstein, P.L.C

20090239865 - Dibenzyl amine compounds and derivatives: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels... Agent: Pfizer Inc. Patent Department

20090239866 - Peptide deformylase inhibitors: Novel PDF inhibitors and novel methods for their use are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090239867 - Therapeutic substituted gamma lactams: v

20090239868 - Inhibitor of pai-1 production: wherein: R1 represents, for example, a hydrogen atom, or a 4-(morpholinyl)carbonyl group, ring D represents, for example, a benzene ring or a benzene ring having substituent(s), and phenyl group E has substituent(s) such as a halogen atom, a halogenated alkyl group, an alkyl group, a halogenated alkoxy group, or an... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090239869 - Therapeutic substituted cyclopentanes: Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.... Agent: Allergan, Inc.

20090239871 - Solubilized topoisomerase poisons: A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic... Agent: Viksnins Harris & Padys Pllp

20090239870 - Spirohydantoin aryl cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2 and R6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The... Agent: Merck And Co., Inc

20090239872 - Treatment of mesothelioma: The present invention relates to a method of treating a warm-blooded animal, especially a human, having mesothelioma, especially malignant mesothelioma, comprising administering to said animal a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative.... Agent: Novartis Corporate Intellectual Property

20090239873 - Phenyl-piperazine derivatives as modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Honigman Miller Schwartz & Cohn LLP

20090239874 - Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds... Agent: Fulbright & Jaworski, LLP

20090239876 - Substituted 4-hydroxypyrimidine-5-carboxamides: The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck And Co., Inc

20090239877 - Novel 1,2,4-triazole derivatives and process of manufacturing thereof: The invention provides 1,2,4-triazole compounds, compositions containing those compounds, methods of treating diseases and/or disorders with those compounds and processes of manufacturing 1,2,4-triazole compounds.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090239875 - Protection of ferulic acid and/or tetramethylpyrazine against retinal ischaemia, glaucoma and siderosis oculi: A method for preventing and/or treating ischaemic and/or iron-related retinal or brain disorders comprising administering an effective amount of ferulic acid (FA), tetramethylpyrazine (TMP) or their pharmaceutically acceptable salt, ester, solvate, hydrate, analogs, metabolite, enantiomer, isomer, tautomer, amide, derivative or prodrug to a subject. The former diseases comprise retinal ischemia,... Agent: Wpat, PC Intellectual Property Attorneys

20090239878 - Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents: The invention relates to combinations of (a) an ATP-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease... Agent: Novartis Corporate Intellectual Property

20090239879 - N-oxides of n-phenyl-2-pyrimidine-amine derivatives: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment... Agent: Novartis Corporate Intellectual Property

20090239881 - Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments: The invention is directed to a combination of flibanserin or a pharmaceutically acceptable derivative thereof and caffeine or a pharmaceutically acceptable derivative thereof for the treatment of Sexual Disorders in humans, particularly women.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090239880 - Combinations of monoamine reuptake inhibitors and potassium channel activators: This invention provides pharmaceutical compositions comprising therapeutically effective amounts of a monoamine reuptake inhibitor and an SK inhibitor. In another aspect the invention provides novel benzoimidazole derivatives for use according to the invention.... Agent: Birch Stewart Kolasch & Birch

20090239882 - Thiazolopyramidine compounds for the modulation of chemokine receptor activity: A compound of formula (I), or a pharmaceutically acceptable salt, or solvate thereof; and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.... Agent: Fish & Richardson P.C.

20090239884 - Methods of treating inflammation: The invention features compositions and methods for treating inflammation and other immune-related disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090239883 - Treatment of pulmonary hypertension: This invention relates to the use of certain cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension.... Agent: Pfizer Inc. Patent Department

20090239885 - Inhibitors of nucleoside phoshorylases and nucleosidases: The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including... Agent: Amster, Rothstein & Ebenstein LLP

20090239886 - Substituted xanthine derivatives: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090239887 - Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating... Agent: Susanne Hollinger, Ph.d, Esq. King & Spalding

20090239888 - Methods for inhibiting amyloid precursor protein and beta-amyloid production and accumulation: Compositions and uses of mGluR5 antagonists for the treatment and inhibition of amyloid precursor protein (APP), Aβ protein, and APP proteolytic products in Alzheimer's disease, Fragile X Syndrome, autism, and Down's Syndrome are provided. The invention provides methods for diagnosing Fragile X Syndrome via the assessment of Aβ1-42 levels in... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090239890 - Spiro substituted cyclopropane compounds for the treatment of inflammatory disorders: m

20090239889 - Spiroindolinone derivatives:

20090239892 - Pyridomorphinans, pyridazinomorphinans and use thereof: OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is C4 cycloalkylalkyl or C4 alkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as... Agent: Connolly Bove Lodge & Hutz LLP

20090239891 - Sustained release dosage forms of analgesic medications: Parenteral extravascular administration of a composition containing an analgesic medication of low water solubility that is dissolved, suspended, or emulsified in a solvent system results in the deposition of the analgesic medication at the site of administration and provides a controlled release of the analgesic medication from the site and... Agent: Howard Eisenberg, Esq.

20090239893 - Stereoselective process and crystalline forms of a camptothecin: A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.... Agent: Lucas & Mercanti, LLP

20090239894 - Stabilized aqueous solutions of ergoline compounds: or their physiologically tolerable salt or derivative, in which R1 stands for an H atom or a halogen atom and R2 stands for an alkyl group or alkenyl group with 1 to 4 carbons and a single or double bond, also containing 0.05% to 90.00% of at least one oxygen-containing... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090239895 - Novel 3-thia-10-aza-phenanthrene derivatives:

20090239896 - Azaindole compounds and use thereof as phospholipase-a2 inhibitors: Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the... Agent: Mcandrews Held & Malloy, Ltd

20090239898 - Further therapeutic use of zolpidem: An imidazo[1,2-a] pyridine-3-acetamide such as zolpidem is useful in the treatment of a condition of the brain which has a lesion and exhibits diaschisis/dormant cells at the contralateral and other sites, more particularly trauma-induced injury, spinocerebellar ataxia, cerebellar or cerebral infarct and Ramsey-Hunt syndrome.... Agent: Rankin, Hill & Clark LLP

20090239897 - Novel compounds: Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090239899 - Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors: v

20090239901 - Method and compositions for treatment of cerebral malaria: A method of treating inflammatory disorders, including cerebral malaria, by administration of modulators of α7 nAChR.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090239900 - Quinine and quinidine salts, methods for making them, and pharmaceutical formulations comprising them: m

20090239902 - Quinine dosage forms and methods of use thereof: Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in... Agent: Cantor Colburn, LLP

20090239903 - Tetrahydroquinoline analogues as muscarinic agonists: The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment... Agent: Knobbe Martens Olson & Bear LLP

20090239904 - Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity: wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such... Agent: Theravance, Inc.

20090239906 - Alkoxyalkyl-substituted cyclic ketoenols: to processes and intermediates for their preparation, and to their use as pesticides and/or microbicides and/or herbicides. The invention further provides selectively herbicidal compositions which comprise alkoxyalkyl-substituted cyclic ketoenols on the one hand and a crop plant tolerance promoter compound on the other. The invention further relates to the boosting... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090239905 - Piperidines and related compounds for the treatment of dementia: Compounds of formula I: modulate the action of gamma secretase, and hence find use in treatment of Alzheimer's disease and related conditions.... Agent: Merck And Co., Inc

20090239907 - Methods and compositions for treating fish diseases: Therapeutic and prophylactic treatments of aquatic species and aquatic diseases through the controlled introduction of a heterocyclic N-halamine into an aquatic habitat.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090239908 - Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene: This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders.... Agent: Hoffman Warnick LLC

20090239909 - Treatment of metabolic syndrome with lactams: The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention.... Agent: Ropes & Gray LLP

20090239910 - Benzenesulfonamide compounds and their use: The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090239911 - Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: The present invention discloses novel compounds of Formula I: having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia,... Agent: Eli Lilly & Company

20090239912 - Concentrated, non-foaming solution of quaternary ammonium compounds and methods of use: A concentrated quaternary ammonium compound (QAC) solution comprising a QAC with a concentration from greater than about 10% by weight and at least one solubility enhancing agent, such as an alcohol, is disclosed. A diluted QAC solution is used to contact food products to prevent microbial growth on the food... Agent: Foley And Lardner LLP Suite 500

20090239913 - Process for the treatment and prevention of diseases caused by fungi: The subject invention is directed to the treatment of infections caused by fungi which are resistant to standard antifungal drugs such as fluconazole. The treatment method involves administering to the sufferer an effective amount of an agent that suppresses the activity of the fungal (H+)-ATPase pump (Pma1p). Such agents may... Agent: Blase C. Billack

20090239914 - Phosphorus binder for treatment of renal disease: The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products... Agent: Kent Barta S.c.

20090239915 - Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals: in which X, R, R1 to R3 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090239917 - Heterocyclic cycloalkyl compounds, a process for their preparation and pharmaceutical compositions containing them:

20090239916 - Novel drug discovery target and medicine acting on the same: The present invention provides a pharmaceutical composition comprising as an active ingredient a compound that specifically binds to MFP-2 or a functional fragment thereof and a screening method for the compound; the compound and a pharmaceutical composition comprising the same are highly useful as anti-inflammatory agents and anti-allergic agents.... Agent: Leydig Voit & Mayer, Ltd

20090239918 - Selective subtype alpha 2 adrenergic agents and methods for use thereof: The invention provides methods for treating pain in mammals. In particular, the invention provides well-defined aminoimidazolines, aminothiazolines, and aminooxazolines and pharmaceutical compositions thereof to treat pain.... Agent: Allergan, Inc.

20090239919 - Glutamate receptor modulators and therapeutic agents: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of... Agent: Richard D. Wood

20090239920 - Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof.... Agent: Pepper Hamilton LLP/wyeth

20090239921 - Methods for treating neoplasms with derivatives of 4,5,6,7-tetrabromobenzimidazole: and at least one inert, pharmaceutically acceptable carrier or diluent; wherein R1 is a hydrogen or an aliphatic group; and R2 is an aliphatic group, optionally substituted with a substituent selected from a hydroxyl and a substituted amino group; and methods of treating human neoplasms and for inhibiting caseine kinase... Agent: Matthias Scholl

20090239922 - Kinesin inhibitors as cancer therapeutics: The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of... Agent: Novartis Vaccines And Diagnostics, Inc.

20090239923 - Concentrated aqueous and/or ethanolic solution of 4-methylpyrazole (fomepizole): A composition of matter comprising fomepizole and water wherein the content of water is about 3% to about 40% by weight, and methods of making fomepizole solutions effective to reduce the freezing point of pure fomepizole to less than about 18° C.... Agent: St. Onge Steward Johnston & Reens, LLC

20090239924 - 1h-furo[3,2-c]pyrazole compounds useful as kinase inhibitors: Furo[3,2-c]pyrazole derivatives of formula (I) as defined in the description, and pharmaceutically acceptable salts thereof, wherein A is an aryl or heteroaryl ring, —NHZR5 is at the ortho position to the CONH linker; —R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom,... Agent: Scully Scott Murphy & Presser, PC

20090239925 - Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are tricyclic indeno-pyrrole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090239926 - Methods for the treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-carboxamide: Methods of treating, managing or preventing psoriasis or psoriatic arthritis are disclosed. Specific methods encompass the administration of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide, alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.... Agent: Jones Day

20090239927 - Statin and omega-3 fatty acids for lipid therapy: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090239929 - N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors: A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R1 is H, C1-6alkyl, —C(A)D, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted; A is S or O; D is H, C1-6alkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl; aryl represents... Agent: Pfizer Inc. Patent Department

20090239928 - N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors: A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R1 is H, C1-6alkyl, —C(A)D, C3-8cycloalkyl, aryl, het, aryl-C1-4alkyl or het-C1-4alkyl, wherein the cycloalkyl, aryl or het groups are optionally substituted by at least one substituent independently selected from C1-8allkyl, C1-8alkoxy, OH, halo, CF3, OCHF2, OCF3, SCF3,... Agent: Pfizer Inc. Patent Department

20090239930 - Therapeutic compounds: c

20090239941 - Amino acid derivatives: Compounds of formula (I) are active as dopaminergic compounds or as compounds which or as compounds which diminish the symptoms of dopamine deficiency: wherein: R1 and R2 are independently selected from —C(═O)R5 or —C(═O)OR5; or one of R1 and R2 is hydrogen and the other is —C(═O)R5 or —C(═O)OR5; R3... Agent: Banner & Witcoff, Ltd.

20090239942 - Topiramate compositions and methods of making and using the same: The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090239943 - Nutraceutical composition and methods for its use: A composition for inhibiting the activity of NF kappa B or for inhibiting tissue damage inflammation due to disease including a combination of green tea polyphenols; resveratrol; soy isoflavones, and curcumin. Also disclosed is a method of inhibiting the activity at the NF kappa B or inflammation using the composition.... Agent: Hoffman, Wasson & Gitler, P.C.

20090239944 - Novel use of organic compounds: wherein R3 is C1-6-alkyloxy, C1-6-acyloxy or aroyloxy; R6 is hydrogen or C1-6-alkyloxy; R7 is C1-6-alkyloxy, C1-6-acyloxy, aroyloxy or arylacyloxy; R8 is hydrogen or C1-6-alkyloxy; or R7 and R8 form together a group O-L-O with L being (CR1R2)n, with R1 and R2 being independently from each other hydrogen or C1-5-alkyl and... Agent: Nixon & Vanderhye, PC

20090239945 - Oral composition with an antiageing effect on the skin: A composition which is adapted for oral consumption and which comprises: (i) a PPAR ligand; such as EPA or DHA (ii) an oestrogen receptor binding agent; such as soy isoflavones (iii) an agent that is involved in the post-translational modification of collagen; such as ascorbic acid and (iv) a carotenoid,... Agent: Unilever Patent Group

20090239946 - Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitors chelate complexes: The present invention provides pharmaceutical compositions of an HDAC inhibitor and a chelatable metal compound. In one embodiment, the invention provides a method of treating cancer and alleviating the side effects of the HDAC inhibitor by administering the pharmaceutical composition. In another embodiment, the present invention also provides pharmaceutical compositions... Agent: Merck And Co., Inc

20090239947 - Inhibition of proliferation and fibrotic response of activated corneal stromal cells: Provided herein are methods of preventing a fibrotic response and/or scarring in a wound, comprising administering to a subject a composition comprising an amount of an amide or ester of an alpha-ketoalkanoic acid effective to inhibit a proliferative and/or fibrotic response in the wound. In one instance, the wound is... Agent: Jesse A. Hirshman, Esq.

20090239948 - Enzymatic production of peracids using perhydrolytic enzymes: A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090239949 - Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same: Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.... Agent: Mcandrews Held & Malloy, Ltd

20090239950 - Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amendable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug components and methods... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090239951 - Crystalline material: The invention relates to novel crystalline forms of 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic acid, said crystalline forms being characterised by a powder X-ray diffraction pattern having major peaks at either 2θ=16.1±0.2, 20.1±0.2, 20.7±0.2, and 24.2+0.2; or 2θ=9.0±0.2, 14.7±0.2, 19.6±0.2, 21.6±0.2, and 24.3+0.2.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090239952 - Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy: The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090239953 - Use of an anti-cancer compound: The present invention relates to a compound represented by the formula (I), method of preparation, pharmaceutical preparation containing said compound, and the use of said compound in the manufacture of a pharmaceutical preparation for the prevention and treatment of cancer by way of inhibiting the proliferation of carcinoma cells of... Agent: Lowe Hauptman Ham & Berner, LLP

20090239954 - Phosphate buffered ophthalmic solutions displaying improved efficacy: The present invention relates to ophthalmic compositions comprising a pH between about 6 and about 8 and about 50 to about 1000 ppm hydrogen peroxide and at least one phosphate buffer. The ophthalmic compositions of the present invention display improved antifungal efficacy against fungi, including candidas albicans and fusarium solani.... Agent: Philip S. Johnson Johnson & Johnson

20090239955 - Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient: e

20090239956 - Lamellar type liquid crystal composition for cosmetic: wherein R represents a linear or branched alkyl, alkenyl, or hydroxyalkyl group; “n” denotes an integer of from 2 to 10; and GL represents a glycerol unit. The cosmetic composition exhibits a superior cleansing power regardless of whether the skin is wet or not, and gives a satisfactory feel during... Agent: Birch Stewart Kolasch & Birch

20090239957 - Stabilized glycerophosphate-containing surgical irrigating solution: One aspect of the present invention relates to stabilized irrigating compositions comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. Another aspect of the present invention relates to methods of irrigating ocular tissues during a surgical procedure comprising bathing the intraocular tissues with an irrigating composition comprising sodium glycerophosphate... Agent: Alcon

  
09/17/2009 > patent applications in patent subcategories. class, title,number

20090233841 - Analgesic conjugates: The present invention relates generally to analgesic compounds having a mu opioid receptor agonist linked to a delta opioid receptor antagonist, and to methods for producing analgesia using such compounds. As compared to opioids such as morphine, these compounds can cause less tolerance, physical dependence, and/or constipation. These compounds are... Agent: Viksnins Harris & Padys Pllp

20090233842 - Fgf2-related methods for diagnosing and treating depression: The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer... Agent: Townsend And Townsend And Crew, LLP

20090233840 - Modified dynorphin expression in animals and identification of compounds for treatment of obesity and diabetes: The present invention provides novel transgenic animal models of reduced dynorphin expression in humans that are useful for identifying compounds that are antagonists, inverse agonists, agonists or mimetics of one or more dynorphin peptide products of preprodynorphin. The compounds identified in such screening assays are useful in contexts related to... Agent: Fenwick & West LLP

20090233843 - Methods and compositions for treating diabetes, metabolic syndrome and other conditions: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and... Agent: Cantor Colburn, LLP

20090233847 - Coupling proteins to a modified polysaccharide: The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified... Agent: Fish & Richardson P.C.

20090233846 - Human luteinizing hormone superagonists: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where... Agent: Nih-ott

20090233845 - Methods and compositions for non-covalently enhanced receptor binding: The invention features contacting (in vitro or in vivo) a receptor-binding ligand with an organic molecule, which can be a small molecule (i.e., an organic molecule that is not a peptide), or a peptide that noncovalently binds to the ligand and either another ligand for the receptor (either a second... Agent: Clark & Elbing LLP

20090233844 - Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified... Agent: Jones Day

20090233859 - Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin: Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dose dependent manner. Disclosed are compositions and methods for modulating diseases... Agent: Suzannah K. Sundby (uc) Smith, Gambrell & Russell, LLP

20090233862 - Compositions and methods for treatment of optic nerve diseases: The present invention provides a method for treating or reducing damage to the optic nerve in a subject comprising administering to the subject a therapeutically effective amount of prostaglandin J2 alone or in combination with an effective amount of GM-CSF. In particular aspects of the invention, the subject is a... Agent: Morgan Lewis & Bockius LLP

20090233855 - Compounds and methods for modulating activation of nf-kb: Compositions and methods for modulating the activation of nuclear factor κB (NF-κB) are provided. The compositions comprise one or more agents that modulate ubiquitination of phosphorylated IκBα and/or IκBβ Such compositions may be used for treating diseases associated with NF-κB activation. Modulating agents include human E3 ubiquitin ligases, antibodies thereto... Agent: Jones Day

20090233850 - Cvn-12p1: a recombinant allosteric lectin antagonist of hiv-1 envelope gp120 interactions: The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of inhibition and with increasing potency versus either component alone. A chimera of the invention combines the high affinity suppression... Agent: Drinker Biddle & Reath LLP One Logan Square

20090233857 - Dna vaccine compositions and methods of use: The present invention is directed to a DNA vaccine for immunization against HIV. The invention comprises a DNA molecule that has a sequence encoding a plurality of viral proteins capable of stimulating an immune response against HIV. The DNA molecule is rendered safe for used as a vaccine by the... Agent: Polsinelli Shughart PC

20090233863 - Hgf preparation: The present invention relates to an HGF preparation comprising HGF and purified sucrose. The HGF preparation is characterized by being stable even after a long-term storage.... Agent: Knobbe Martens Olson & Bear LLP

20090233851 - Insulin resistance improver: A novel dosage regimen of GLP-1 receptor agonists causes little or no side effects or drug interactions and is suitable for improving insulin resistance. Also provided is an insulin resistance improver for use in the dosage regimen. The dosage regimen comprises repeatedly administering, preferably in a non-invasive manner, a GLP-1... Agent: Drinker Biddle & Reath (dc)

20090233852 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090233860 - Lytic domain fusion constructs and methods of making and using same: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090233861 - Lytic domain fusion constructs and methods of making and using same: The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090233864 - Novel antibiotic alternatives: The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and... Agent: Mckee, Voorhees & Sease, P.L.C

20090233854 - Novel application of apelin: The present invention provides a preventive/therapeutic agent for mood disorders or drug dependence, and so on. A pharmaceutical composition of the present invention comprising a substance promoting the function of an apelin receptor APJ or the like is useful as the preventive/therapeutic agent for mood disorders, drug dependence, etc.... Agent: Sughrue Mion, PLLC

20090233865 - Nutritional compositions: The present inventors discovered that the onset of galactosamine hepatopathy is suppressed by nutritional compositions comprising as essential ingredients: whey protein hydrolysates; lecithin and oils and fats high in oleic acid, which are able to improve the lipid metabolism; and palatinose having an insulin-sparing effect. Furthermore, the whey protein hydrolysate... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090233848 - Pea15 as a tumor suppressor gene: The present invention relates generally to the fields of cancer therapy and gene therapy. More particularly, the invention is directed to PEA15 as a treatment for cancer. In a particular embodiment, PEA15 acts as a tumor suppressor for treatment of the cancer. In another particular embodiment, the cancer cells comprises... Agent: Fulbright & Jaworski, LLP

20090233849 - Recombinant alpha-fetoprotein, method and means for preparation thereof, compositions on the base thereof and use thereof: The invention relates to the microbiological and medical industry, genetic engineering, biotechnology. A Saccharomyces cerevisiae yeast strain was obtained on the basis of constructing a recombinant plasmid DNA comprising a structural gene of a human alpha-fetoprotein (AFP) under the control of a regulatory promoter, providing the synthesis and production of... Agent: Howson & Howson LLP

20090233858 - Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation: Embodiments of the present invention relate to crystals and atomic coordinates for PP2A, as well as methods for using these atomic coordinates to prepare modulators of PP2A and inhibitors prepared using such methods. Further embodiments relate to biochemical analyses of the interactions of PP2A alone or in complex with Tau.... Agent: Pepper Hamilton LLP

20090233856 - Synthetic mecp2 sequence for protein substitution therapy: The invention relates to the MeCP2 protein and its use in protein substitution therapy. More specifically, the invention relates to condon-optimized nucleic acid sequences for the expression of MeCP2 proteins, methods for creating such a nucleic acid sequence and expressing such a protein, fusions of a protein of the invention... Agent: Birch Stewart Kolasch & Birch

20090233853 - Use of outer membrane protein a in treatment/prevention/diagnosis of bacterial infection in central nervous system and/or peripheral blood circulation: The present invention provides a method for the treatment and/or prevention of bacterial infection in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided is an antibody binding to OmpA that... Agent: Wpat, PC Intellectual Property Attorneys

20090233869 - Psi-epsilon rack peptide composition and method for protection against tissue damage due to ischemia: A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.... Agent: King & Spalding LLP

20090233866 - Screening methods and the use of agents identified using the same: A method for isolating candidate peptides for the treatment of a disease or disorder with a causative agent with SOD activity, the method comprising the steps of: (i) contacting a plurality of candidate peptides with a first agent with SOD activity and being causative of the disease or disorder and... Agent: Frommer Lawrence & Haug

20090233868 - Small antiviral peptides against hepatitis c virus: Disclosed herein is a small 7 amino-acid peptide, corresponding to the C terminus of RRM2 of the human La protein that binds to the IRES element of hepatitis C virus RNA and its derivatives. This disclosure demonstrates that this 7-mer interacts with the HCV IRES element both in vitro and... Agent: Lathrop & Gage LLP

20090233867 - Treatment of ocular wounds and ulcers: A method for treating ocular conditions such as bacterial keratitis, bacterial conjunctivitis, corneal ulcers and wounds, endophthalmitis, and blebitis in mammals, by using a native, synthetic, or recombinant CAP37, or effective peptide portions thereof including CAP37 peptides 20-44, 23-42, 102-122, and 120-146 and monocysteine derivatives of peptides 20-44 and 23-42.... Agent: Dunlap Codding, P.C.

20090233870 - Antimicrobial peptides: The present invention relates to peptides with antimicrobial or endotoxin-neutralizing activity having the general formula (Xaa1)M-(Xaa2)0-Xaa3-(Xaa4)P-(Xaa5)Q-(Xaa6)M-(Xaa7)R-(Xaa8)S.... Agent: Fulbright & Jaworski L.L.P.

20090233871 - Complexed polypeptide and adjuvant for improved vaccines: Immunogenic polypeptides having the capability to precipitate and focus a CpG adjuvant exhibit enhanced in vivo priming of a cytotoxic T-lymphocyte (CTL) response. Accordingly, compositions that include a bipartite immunogenic polypeptide are provided herein. The bipartite polypeptide includes a CpG-interacting amino acid sequence and a CTL-activating amino acid sequence. Also... Agent: Fish & Richardson PC

20090233872 - Therapeutic agent for neurodegenerative disease: [Means for Solving Problems] It is known that DJ-1 protein is involved in Parkinson's disease and is capable of inhibiting neuronal cell death caused by oxidative stress. Based on this knowledge, screening is made for a low molecular weight molecule capable of binding to an active site of DJ-1 protein... Agent: Edwards Angell Palmer & Dodge LLP

20090233873 - Nitric oxide donors: The invention relates to novel NO donors which are targeted to the mitochondria. The NO donor compounds of the invention allow NO to be selectively provided to the mitochondria.... Agent: Merchant & Gould PC

20090233874 - Process for the preparation of compounds useful as inhibitors of sglt: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.... Agent: Philip S. Johnson Johnson & Johnson

20090233875 - Glycolipids and analogues thereof as antigens for nk t cells: This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090233876 - Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives: The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090233877 - Avermectin compounds and treatment of dermatological disorders therewith: Compounds of the natural avermectin family are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090233985 - Compositions and methods for inhibiting hiv infections by inhibiting lerepo4 and glipr: The present invention relates to inhibitor molecules of LEREPO4 or GliPR or respective functional homologues thereof including siRNAs, shRNAs, antisense RNAs, antisense DNA and dominant negative proteinaceous mutants of LEREPO4 or functional homologues thereof. The present invention also relates to pharmaceutical compositions and methods for preventing and/or inhibiting HIV infections... Agent: Knobbe Martens Olson & Bear LLP

20090233981 - Compounds for hydrolyzing ribonucleic acids (rna's): The present invention relates to a method and compounds for hydrolysing nucleic acids. In particular it relates to compounds that can be used for the preferential cleavage of a phosphodiester bond at a specific position in RNA.... Agent: Abelman Franyne & Schwab

20090233982 - Methyltransferases and their uses: The identification and cloning of Misu polypeptide are disclosed and in particular full length human and murine Misu polypeptides. The Misu polypeptides are shown to have methyltransferase activity for a range of nucleic acid substrates. The uses of these polypeptides and nucleic acid molecules are disclosed, for example for screening... Agent: Foley & Lardner LLP

20090233983 - Rna interference mediated inhibition of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering rna: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications associated with insulin response. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against PTP-1B... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20090233984 - Rnai modulation of rsv and therapeutic uses thereof: The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based... Agent: Alnylam/fenwick

20090233993 - Compositions and methods for inhibiting gsk3 activity and uses thereof: Disclosed herein are compositions and methods relating to peptides. The peptides can inhibit amyloid beta (Aβ) generation and reduce GSK-3 activities. Further provided are compositions and methods for treating or preventing, for example, Alzheimer's disease, cancer, and diabetes.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090233990 - Generation of biological pacemaker activity: Compositions and methods for enhancing hyperpolarization-activated cation inward current and disrupting inwardly rectifying potassium current of cells are described. The compositions and methods may be employed to cause the cells to become biological pacemaker cells, e.g. to become more like SA node cells, and to undergo spontaneous oscillating action potentials.... Agent: Campbell Nelson Whipps, LLC

20090233991 - Generation of biological pacemaker activity: Compositions and methods for enhancing hyperpolarization-activated cation inward current and disrupting inwardly rectifying potassium current of cells are described. The compositions and methods may be employed to cause the cells to become biological pacemaker cells, e.g. to become more like SA node cells, and to undergo spontaneous oscillating action potentials.... Agent: Campbell Nelson Whipps, LLC

20090233992 - Hepatitis c virus vaccine: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell... Agent: Merck And Co., Inc

20090233987 - Method and apparatus for drug delivery to tissue or organ for transplant: It is intended to provide a method for delivering a drug such as a gene to a tissue or organ for transplant such as skin by use of a laser-induced stress wave (LISW) and thereby producing a high-performance tissue or organ for transplant with a high survival ability and to... Agent: Birch Stewart Kolasch & Birch

20090233986 - Methods and compositions for using sax2: The present invention is generally directed to factors involved in energy metabolism. More specifically, a new gene is identified and shown to be a homeobox Sax2 gene that is involved with an obesity phenotype. Deletion of the causes growth retardation starting at birth and high postnatal lethality. Further, abrogation of... Agent: Marshall, Gerstein & Borun LLP

20090233994 - Novel glutamic acid decarboxylase (gad) chimera and methods of use: The invention relates to a novel Glutamic Acid Decarboxylase (GAD). More specifically, novel DNA and protein sequences relating to GAD. Additionally, the invention discloses a novel composition and related methods for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, epilepsy, and the like, using viral and non-viral delivery systems... Agent: Nutter Mcclennen & Fish LLP

20090233989 - Oligonucleotides stimulatory of the mesenchymal stem cell proliferation and uses thereof: Oligonucleotides having the ability to greatly stimulate the proliferation of pluripotent mesenchymal stem cells “in vitro” and “in vivo” of animals, including humans, are disclosed. These oligonucleotides can be used in a wide range of clinical procedures such as (1) regeneration of mesenchymal tissues which have been damaged through acute... Agent: Defillo & Associates, Inc.

20090233988 - Therapeutic agents for diseases associated with apoptotic degeneration in ocular tissue cells that use siv-pedf vectors: The present invention provides novel methods for treating diseases associated with apoptotic degeneration in ocular tissue cells by effective administration of pigment epithelium derived factor (PEDF). The present inventors studied PEDF as a means to prevent ganglion cell death, the final pathology of glaucoma. The present invention is particularly focused... Agent: Clark & Elbing LLP

20090233878 - Novel adenosine a3 receptor agonists: wherein Ar, R and R1 have a meaning as defined herein in the specification. Compounds of formula (I) are agonists of the A3 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A3 adenosine receptor. Accordingly, the compounds of formula (I) may be employed... Agent: Christopher Klein King Pharmaceuticals, Inc.

20090233879 - Novel nucleoside derivatives: The present patent application relates to the novel nucleoside derivatives and novel intermediates, which are useful to antiviral, anti tumor and immunomodulatory activity, method of treating diseases, conditions and/or disorders modulated by viral infections with them, and processes for preparing them.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090233880 - Equol production accelerating composition: A composition which can significantly accelerate equol production is provided. When formulated in a pharmaceutical preparation or a food or drink, this composition exerts effects of preventing a vascular disease by the cholesterol lowering function, preventing breast cancer or prostatic cancer, and preventing and/or treating osteoporosis. Also, when formulated in... Agent: Sughrue-265550

20090233881 - Compounds having anti-cancer properties: There is provided a method for alleviating symptoms, treating or preventing cancer, the method comprising administering to a subject, having or at risk of developing cancer, a pharmaceutical formulation comprising an effective amount of one or more phosphate derivatives of one or more hydroxy chromans selected from the group consisting... Agent: Michael Best & Friedrich LLP

20090233882 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis employing. The methods... Agent: Honigman Miller Schwartz & Cohn LLP

20090233883 - Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same: e

20090233884 - Use of cyclipostin derivatives for the treatment of mycobacterial infectious diseases:

20090233885 - Compositions and methods for fat reduction: Compositions, methods, and apparatuses for treatment of subcutaneous fat tissue for the purpose of fat tissue reduction or other alterations of the subcutaneous fat tissue which affect the appearance of the overlying skin layer.... Agent: Cr Miles, P.C. Craig R. Miles

20090233886 - Derivatives of 4- or 5-aminosalicylic acid: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon... Agent: Bennett Jones LLP C/o Ms Roseann Caldwell

20090233887 - Hydroswellable, segmented, aliphatic polyurethanes and polyurethane ureas: Hydroswellable, absorbable and non-absorbable, aliphatic, segmented polyurethanes and polyurethane-urea capable of swelling in the biological environment with associated increase in volume of at least 3 percent have more than one type of segments, including those derived from polyethylene glycol and the molecular chains are structurally tailored to allow the use... Agent: Leigh P. Gregory

20090233888 - Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth: The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut. An H2S or lactulose breath test and/or detection of... Agent: Davis Wright Tremaine LLP/los Angeles

20090233889 - Stabilized 1,25-dihydroxyvitamin d2 and method of making same: A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20090233890 - Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection: Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.... Agent: Alcon

20090233891 - Pharmaceutical lotion comprising fluticasone propionate: The present invention generally relates to a pharmaceutical composition. More particularly, the present invention relates to a stable topical lotion comprising at least a therapeutically effective amount of an androstane steroid compound or a pharmaceutically acceptable salt or ester thereof and one or more occlusive agents.... Agent: Glenmark Pharmaceuticals Inc Usa

20090233892 - Topical compositions comprising hydrocortisone butyrate: The present invention generally relates to a a topical composition, such as a dermatological cream, containing the corticosteroid compound hydrocortisone butyrate.... Agent: Glenmark Pharmaceuticals Inc Usa

20090233893 - Methods of dissolving beta-sheet proteins and uses thereof: The application discloses metallized chelator complexes and uses of metallized chelator complexes for dissolving β-sheet proteins and reducing formation of β-sheet proteins, where the metallized chelator complex comprises a metal ion chelator and a metal ion.... Agent: Alan D Miller Amster Rothstein & Ebenstein

20090233894 - Compounds and methods for the treatment of cancer: The present invention provides organic arsenicals which may be used to treat numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.... Agent: Ropes & Gray LLP

20090233895 - Method of treatment of bacterial infections: The present invention relates to a method of treatment of bacterial infections including administering an effective amount of an oral time-dependent antibiotic to a human or warm blooded animal.... Agent: Buchanan, Ingersoll & Rooney PC

20090233898 - Pharmaceutical compositions comprising simvastatin and ezetimibe: The present invention generally relates to a stable pharmaceutical composition that does not have a film coating which contains simvastatin, ezetimibe or pharmaceutically-acceptable salts thereof, and ascorbic acid.... Agent: Glenmark Pharmaceuticals Inc Usa

20090233899 - Crystalline modification of cefuroximaxetil: A novel crystalline modification of cefuroximaxetil (ε-modification), pharmaceutical compositions containing this modification, and their use.... Agent: Crowell & Moring LLP Intellectual Property Group

20090233896 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20090233897 - Potassium channel inhibitors: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20090233900 - 2-aminobenzamide derivative: The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090233903 - Azetidine and cyclobutane derivatives as jak inhibitors: The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.... Agent: Fish & Richardson PC

20090233902 - Indolopyridines as eg5 kinesin modulators: Compounds of a certain formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.

20090233904 - Macrocyclic spiro pyrimidine derivatives: Macrocyclic spiro pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.... Agent: Paul D. Yasger Abbott Laboratories

20090233901 - Vla-4 inhibitory drug: c

20090233905 - Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer: The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.... Agent: Dilworth & Barrese, LLP

20090233906 - Imidazoazepinone compounds: The invention relates to compounds of formula (I): along with pharmaceutical compositions containing the same and methods of use thereof.... Agent: Myers Bigel Sibley & Sajovec

20090233907 - Pyridopyrimidine derivatives and their use as pde4 inhibitors: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE 4 mediated disease state.... Agent: Fish & Richardson P.C.

20090233908 - Nitrogenous heterocyclic compound and medicinal use thereof: The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection... Agent: Sughrue-265550

20090233909 - Sulfonamide compounds as cysteine protease inhibitors: The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for... Agent: Townsend And Townsend And Crew, LLP

20090233910 - Npy antagonists, preparation and uses: The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological... Agent: Buchanan, Ingersoll & Rooney PC

20090233911 - Thiadiazole derivatives for the treatment of neurodegenerative diseases: This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for... Agent: Clark & Elbing LLP

20090233912 - Non-aqueous pharmaceutical composition: A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100%... Agent: Panitch Schwarze Belisario & Nadel LLP

20090233913 - Optical isomers of dihydro-2,3-benzodiazepines and their stereoselective synthesis: The present invention relates to dihydro-2,3-benzodiazepine compounds of high enantiomeric purity according to the general formula (I), which contain an asymmetric centre at the position 4 of the dihydro-2,3-benzodiazepine compound, and the preparation thereof and the used intermediates as well. These compounds have anti-convulsiveA muscle relaxant and neuroprotective effect due... Agent: K.f. Ross P.C.

20090233914 - Composition for treatment of nail infections: The present invention includes a composition for treating fungal infections, particularly onychomycosis. The composition includes a photosensitizer, an effective amount of antifungal agent, and a pharmaceutically acceptable delivery system.... Agent: Dobrusin & Thennisch PC

20090233915 - 5-substituted-2-phenylamino benzamides as mek inhibitors: e

20090233916 - Method of inducing virus tolerance of plants: A method of inducing virus tolerance of plants which comprises treating the plants, the soil or seeds with an effective amount of a combination of a compound of the formula (I) in which the variables have the meaning as set forth in the description, and a second active compound as... Agent: Brinks, Hofer, Gilson & Lione

20090233917 - Stroke recovery: The present invention provides methods of treating stroke comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. The invention also provides pharmaceutical compositions comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or... Agent: Ropes & Gray LLP

20090233918 - 2-(cyclic amino)-pyrimidone derivatives: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the... Agent: Greenblum & Bernstein, P.L.C

20090233920 - Organic compounds: The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation... Agent: Novartis Corporate Intellectual Property

20090233919 - Thiazolopyridinone derivates as mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R1, q, p, R2, t, Ar1, L1, R3 and R4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity... Agent: Eli Lilly & Company

20090233921 - Therapeutic cyclopentane derivatives: e

20090233922 - Method for treating neuronal and non-neuronal pain: A method for the combined treatment of neuronal and non-neuronal pain in mammals is provided comprising administration of adenylyl cyclase 1 inhibitors having the following general formula (1): (1) wherein: G, H, J and M are each N, or H and J are each C, and G and M are... Agent: Valentine A Cottrill Susan Tandan

20090233923 - Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof: m

20090233926 - 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders: The invention concerns pyrimidine derivatives of Formula (I), wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in... Agent: Astrazeneca R&d Boston

20090233925 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090233924 - Quinazoline derivatives: The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them... Agent: Morgan Lewis & Bockius LLP

20090233927 - 2-aminoquinolines: wherein R1 and R2 are as described herein and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them, and methods for their manufacture. These compounds are 5-HT5A receptor antagonists, useful for the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090233929 - Imidazole derivatives for the treatment of anxiety and related diseases: e

20090233928 - Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation:

20090233930 - Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20090233931 - Therapeutic compounds: i

20090233932 - Novel crystalline forms of lamotrigine: The present invention relates to novel crystalline forms of lamotrigine, to processes for their preparation and pharmaceutical compositions containing them.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090233933 - Prostaglandin transporter inhibitors: Provided are methods of inhibiting prostaglandin transporter (PGT) activity in mammals. Also provided are methods of determining whether a test compound is an inhibitor of a prostaglandin transporter. Additionally provided are compounds that inhibit prostaglandin transporter activity, and pharmaceutical compositions of those compounds. Methods of inhibiting COX-2 in a mammal... Agent: Amster, Rothstein & Ebenstein LLP

20090233934 - Pyrazinecarboxamide derivatives and plant disease controlling agents containing the same: [wherein X is a halogen atom or an (C1-C3)alkyl group which may be substituted with a halogen atom(s); Y is a hydrogen or halogen atom, or a cyano, a (C1-C3)alkyl or (C1-C3)alkoxy group; R is a hydrogen or halogen atom, a cyano group, or a (C1-C6)alkyl, (C2-C6)alkenyl group, (C2-C6)alkynyl, (C1-C6)alkoxy,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090233935 - Methods for fabrication of antimicrobial surfaces: A method for rendering a carboxyl-containing polymer surface resistant to microbial growth, the method comprising: (i) reacting the carboxyl-containing polymer surface with a metal borohydride in a solvent system comprising a water-soluble alcohol having one to three hydroxy groups and one to four carbon atoms, and optionally up to about... Agent: Hoffmann & Baron, LLP

20090233936 - Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted fused aminopiperidines of structural formula (I) which are inhibitors of the dipeptidyl peptidase-4 enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-4 enzyme is involved, such as diabetes and particularly Type 2 diabetes. The... Agent: Merck And Co., Inc

20090233937 - Fused heterocyclic compound: e

20090233938 - Thiazole derivatives as a2b antagonists: Compounds of formula (I) in free or salt form, where Ar is phenyl substituted by one or more substituents selected from halogen, cyano and C1-C8-haloalkyl, or naphthyl, R1 is hydrogen, phenyl optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-alkoxy-C1-C8 alkyl, carboxy, C1-C8-alkoxycarbonyl... Agent: Novartis Institutes For Biomedical Research, Inc.

20090233939 - Treatment of amm: The present invention relates to a method of treating a warm-blooded animal, especially a human, having agnogenic myeloid metaplasia (AMM), especially agnogenic myeloid metaplasia which is resistant to conventional chemotherapy.... Agent: Novartis Corporate Intellectual Property

20090233940 - Insecticide compositions: An insecticide composition is provided for killing insects comprising a metal sequestering agent and an insecticide. The composition is particularly useful for killing scale insects, particularly Cycad Asian Scale insects that are hosted by plants of the cycad phyta division. Since the scale insect's shell includes calcium, the metal sequestering... Agent: Timothy H. Van Dyke Beusse Wolter Sanks Mora & Maire, P.A.

20090233941 - Co-crystals of calixarenes and biologically active molecules: This invention relates to co-crystals of at least one molecule of calyx[n]arene or at least one of its derivatives, and at least one biologically active molecule, compositions and medicines including them, and the use of these co-crystals and methods used to obtain them.... Agent: Arent Fox LLP

20090233942 - Genetic markers associated with response to antidepressants: Markers of the ACE, ATP5C3, BCL2L1, CYP2C9, DRD3, FOS, DTNBP1, GABRG3, GRIA4, LAMA4, MAPK1, NPY1R, OPRD1, OPRM1, PER3, PLCB1, PSMD1, ABI1, LOC402382, and NCALD genes, and their association with response to antidepressants are disclosed. Compositions and methods for detecting and using these markers in a variety of clinical applications are... Agent: Ropes & Gray LLP

20090233943 - New compounds 835: r

20090233944 - Pyrazine-2-carboxyamide derivatives:

20090233945 - New compounds 834:

20090233946 - Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation: Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.... Agent: Brinks Hofer Gilson & Lione

20090233947 - 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones which modulating the function of the vanilloid -1 receptor (vr1): Compounds of formula (I) which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).... Agent: Merck And Co., Inc

20090233948 - Inhibitors of nucleoside phosphorylases and nucleosidases: The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including... Agent: Amster, Rothstein & Ebenstein LLP

20090233950 - Quinazoline derivatives: or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use... Agent: Morgan Lewis & Bockius LLP

20090233951 - Parenteral solutions containing metolazone: Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylactamide, polyethylene glycol and D5W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.... Agent: Gildo E. Fato Office Of Laurence M. Dunlap

20090233949 - Isoserine derivatives for use as coagulation factor ixa inhibitors: s

20090233953 - Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof:

20090233952 - Substituted cycloalkene derivative: Provided that in the case where R3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090233954 - Methods and systems for prognosis of a patient's response to treatment of androgenetic skin disorders: Methods and systems are described for prediction of a patient's response to a drug for treating androgenetic skin disorders such as alopecia, acne, and hirsutism. For a given drug such as anti-androgens and 5-alpha-reductase inhibitors, and a given dosage, the likely responsiveness of that drug and dosage may be determined,... Agent: Nixon Peabody LLP

20090233955 - 1h-pyrrolo[2,3-b]pyridnes: Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090233956 - Novel pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors: r

20090233958 - (+)-beloxepin and methods for its synthesis and use: This present disclosure provides compositions comprising (+)-beloxepin, methods for their synthesis and methods for their use.... Agent: Dechert LLP

20090233957 - (-)-beloxepin and methods for its synthesis and use: This present disclosure provides compositions comprising (−)-beloxepin, methods for their synthesis and methods for their use.... Agent: Dechert LLP

20090233959 - Beloxepin and analogs for the treatment of pain: This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.... Agent: Dechert LLP

20090233960 - Kinase inhibitors: The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula I, II, or III or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, I II III wherein X, R1, R2, R3, R31, n, and m have the meaning defined in... Agent: Wolf Greenfield & Sacks, P.C.

20090233961 - Tartrate derivatives for use as coagulation factor ixa inhibitors: e

20090233962 - Amide derivative and insecticide containing the same: wherein, in the formula, A1, A2, A3 and A4 each represent a carbon atom or the like; R1 and R2 each represent a hydrogen atom or the like; G1 and G2 represent an oxygen atom or the like; Xs each represent a hydrogen atom, a halogen atom or the like;... Agent: Buchanan, Ingersoll & Rooney PC

20090233963 - Methods to determine suceptibility to treatment with leukotriene modifiers: The present invention provides a method of determining the susceptibility of a subject to treatment with a leukotriene modifier by determining the subject's cysteinyl leukotriene (CysLT) level and the subject's level of eosinophilic airway inflammation and identifying a subject with a high ratio of CysLT levels to eosinophilic airway inflammation... Agent: Sheridan Ross PC

20090233964 - Methods for improving the pharmacokinetics of hiv integrase inhibitors: The invention provides methods for improving the pharmacokinetics of an HIV integrase inhibiting compound by administering food and/or ritonavir or a pharmaceutically acceptable salt thereof with the HIV integrase inhibitor.... Agent: Viksnins Harris & Padys Pllp

20090233965 - Alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder: The invention provides compounds of formula (I), wherein R1, R2, R3, R4, R5 and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions and their use in therapy (I).... Agent: Fish & Richardson P.C.

20090233966 - Analogues of the azinomycins as anti-tumour agents and as prodrugs: Compounds of general formula (I) or a salt thereof in which R1 is preferably an aromatic DNA binding subunit are oxidation-activated prodrugs. The compounds are expected to be converted into an epoxide at the alkene to which R2 is attached by cytochrome P450, in particular CYPIBI, expressed at high levels... Agent: Oliff & Berridge, PLC

20090233967 - Crystalline forms of mc4r agonist and process for synthesis: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.... Agent: Merck And Co., Inc

20090233969 - Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation: e

20090233968 - Inhibitors of the alpha2beta1/gpia-iia integrin: Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity.... Agent: Woodcock Washburn LLP

20090233970 - Combined nsaid and acid blocker formulation and method: The present invention is directed to co-administration of a non-steroidal anti-inflammatory agent (NSAID) and acid blocking agent for the treatment of pain and inflammation with reduced gastrointestinal irritation. A pharmaceutical composition suitable for the co-administration contains a therapeutically effective amount of at least one non-steroidal anti-inflammatory agent, and a therapeutically... Agent: Stetina Brunda Garred & Brucker

20090233971 - Gsk-3 inhibitors: wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are... Agent: King & Spalding

20090233973 - Epothilone derivatives for the treatment of multiple myeloma: e

20090233972 - Substituted heterocycles as anti-infectives: which inhibit RNA-containing viruses, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090233974 - Substituted gamma lactams as therapeutic agents: i

20090233975 - Hair resiliency/body improver and hair cosmetic:

20090233976 - Antimitotic rhizoxin deritivatives of burkholderia rhizoxina, method for producing said derivatives and use thereof:

20090233977 - Method of treating atherosclerosis, dyslipidemias and related conditions: A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.... Agent: Merck And Co., Inc

20090233978 - Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.... Agent: Jeffrey J. King, Esq. Black Lowe & Graham PLLC

20090233979 - Indole derivatives and their use as thyroid receptor ligands: The invention provides compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, (I) wherein R1, R2, R3, R4, R5, R6, Y and W are as defined in the specification. The invention... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090233980 - Substituted gamma lactams as therapeutic agents: e

20090233995 - Use of drug combinations for treating insulin resistance: The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and/or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with... Agent: Merchant & Gould PC

20090233996 - Avermectin/benzoyl peroxide compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090233997 - Composition for promoting synthesis of collagen, and composition for external preparation for skin comprising the same: The present invention relates to a composition for promoting collagen synthesis and a composition for external application to skin which includes the collagen synthesis promoting composition. The collagen synthesis promoting composition includes, as an effective component, at least one selected from the group consisting of compounds represented as: wherein R... Agent: Ladas & Parry

20090233999 - Compositions and therapeutic methods involving isoflavones and analogues thereof: Isoflavone compounds and analogues thereof, compositions containing same and therapeutic methods of treatment involving same are described.... Agent: Sughrue Mion, PLLC

20090233998 - Desmosdumotins, the method for preparing the same and use as anti-tumor or anti-aids agents: This invention discloses the method for preparing desmosdumotin C, the series of desmosdumotin C derivatives and their manufactures, and the total synthesis of desmosdumotin B. The invention also discloses uses of the derivatives and pharmaceutical compositions containing the same in preparation of medicines for treatment of tumor or AIDS.... Agent: Pearl Cohen Zedek Latzer, LLP

20090234000 - Triptolide analogs for the treatment of autoimmune and inflammatory disorders: The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds.... Agent: King & Spalding

20090234001 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, R1, RP, ZP, LP1, LP2 LNP, RP3, RN, and ZNP are defined herein, their preparation, pharmaceutical compositions, and methods of use.... Agent: Eli Lilly & Company

20090234002 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090234003 - Carbamate compounds for use in preventing or treating anxiety disorders: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20090234004 - Pharmaceutical compositions having desirable bioavailability: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as... Agent: Alcon

20090234005 - Protective agent for retinal neuronal cell containing prostaglandin f2alpha derivative as active ingredient: An object of the present invention is to find a new pharmaceutical application of a prostaglandin F2α derivative. It was found that the prostaglandin F2α derivative inhibits glutamate-induced retinal neuronal cell death in a concentration-dependent manner in rat fetal retinal neuronal cells, in other words, the prostaglandin F2α derivative acts... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090234006 - Method for producing arachidonic acid and/or eicosapentaenoic acid in useful transgenic plants: The invention relates to a method for producing arachidonic acid and/or eicosapentaenoic acid in useful transgenic plants, according to which nucleic acids, which encode polypeptides with Δ-6-desaturase activity, Δ-6-elongase activity or Δ-5-desaturase activity, are introduced into the plants. As an added advantage, a gene that encodes a Δ-3-desaturase is expressed... Agent: Connolly Bove Lodge & Hutz, LLP

20090234008 - Method of using catalpic acid to treat and prevent dyslipidemia, type 2 diabetes, and associated disorders: A method of treating and preventing dyslipidemia, cardiovascular disease, type 2 diabetes, obesity and other diseases associated with the Metabolic Syndrome and of increasing the expression of genes that promote lipid oxidation in an animal, including mammals and humans, in which a therapeutically effective amount of catalpic acid is administered... Agent: Intellectual Property Dept. Dewitt Ross & Stevens Sc

20090234007 - Unsaturated fatty acids as thrombin inhibitors: A preparation having at least one unsaturated fatty acid and the use of at least one unsaturated fatty acid having a chain length of 18 or 20 carbon atoms and of plant drugs containing the unsaturated fatty acid as a free fatty acid or a fatty acid radical of a... Agent: D. Peter Hochberg

20090234009 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090234010 - Manufacture process of organic compounds: The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof and their derivatives, e.g. their salts. In particular, the present invention relates to a method of preparing (N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate.... Agent: Novartis Corporate Intellectual Property

20090234011 - N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress: Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090234012 - Administration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes: A method of treating neurotransmitter dysfunction in a patient by optimizing catecholamine levels by administration of L-3,4-dihydroxyphenylalanine (L-Dopa or Dopa) precursors in combination with a source of L-Dopa. The dopa precursor is preferably administered in such quantities such that the amount of dopa from the dopa precursors does not fluctuate... Agent: Vidas, Arrett & Steinkraus, P.A.

20090234013 - Pharmaceutical compositions having desirable bioavailability: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as... Agent: Alcon

20090234014 - Naphthalene-disulfonamides useful for the treatment of inflammation: There is provided compounds of formula (I), wherein R1, R2, X2, X4 and X5 to X8 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired... Agent: Morgan Lewis & Bockius LLP

20090234015 - Anti-inflammatory quinic acid derivatives for oral administration: Disclosed are compounds comprising analogs of quinic acids or shikimic acids having anti-inflammatory properties. The compounds are suitable for oral administration, stable, and demonstrate significant efficacy in inhibiting NF-kB, inhibiting leukocyte adhesion, and inhibiting other factors and cytokines known to be involved in inflammatory disease.... Agent: Donna J. Russell

20090234016 - Compounds for the treatment of metabolic disorders: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, 4 or 5; q is 0 or 1; t is 0 or... Agent: Wellstat Management Company. LLC

20090234018 - Non-standard amino acid conjugates of amphetamine and processes for making and using the same: Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed.... Agent: Mcandrews Held & Malloy, Ltd

20090234017 - Treating skin disorders: This document relates to methods and materials involved in treating skin disorders. For example, methods and materials for using an alpha adrenergic receptor agonist (e.g., midodrine) to treat mammals having a skin disorder are provided.... Agent: Fish & Richardson P.C.

20090234019 - T type calcium channel inhibitors: i

20090234020 - Processes for the preparation of odesmethylvenlafaxine, free from its dimer impurities: The present invention provides isolated O-desmethylvenlafaxine impurities ODV-Dimer and ODV-N-Dimer, their use as a reference marker and reference standard, and a process for the preparation of O-desmethylvenlafaxine free from said impurities... Agent: Kenyon & Kenyon LLP

20090234021 - Treatment of demyelinating conditions: The present invention provides novel methods and compositions for the treatment of multiple sclerosis.... Agent: Adamas Pharmaceuticals, Inc.

20090234022 - Formulations of vitamin k analogs for topical use: The present invention provides topical formulations containing a vitamin K analog, e.g., menadione, that deliver a uniform, therapeutically effective concentration of the vitamin K analog to the skin in a vehicle which is stable, non-irritating, non-drying and cosmetically acceptable. These topical formulations are useful for the treatment and prevention of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090234023 - Substituted hydroxyacetophenone derivatives: The present invention relates to substituted hydroxyacetophenone derivatives having antiproliferative and antimicrobial properties, to pharmaceutical compositions containing them, as well as to a method of preparing them. Moreover, the hydroxyacetophenone derivatives according to the invention can serve as organic intermediates for the preparation of biologically active compounds.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090234024 - Estrogenic compounds, process for their production and pharmaceutical uses thereof: in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the... Agent: Dunlap Codding, P.C.

20090234025 - Protective surface film for a liquid: A composition and method of protecting the protection of an exposed body of water comprising 5-95 wt % silicone polymer; greater than zero percent to 90 wt % carrier material; and greater than zero −20 wt % surfactant. The method includes the steps of adding the composition to the surface... Agent: Charles C. Mccloskey

20090234026 - Concentrated aqueous silk fibroin solution and use thereof: The present invention provides for concentrated aqueous silk fibroin solutions and an all-aqueous mode for preparation of concentrated aqueous fibroin solutions that avoids the use of organic solvents, direct additives, or harsh chemicals. The invention further provides for the use of these solutions in production of materials, e.g., fibers, films,... Agent: David S. Resnick

20090234027 - Topical gel cosmetic formulation of cellacefate for the control of acne and rosacea: Compositions for the treatment of acne or rosacea on the skin are described. Also provided are methods of forming the compositions as well as the treatment itself. The composition includes as an active ingredient cellulose acetate phthalate (CAP).... Agent: Thomas A. O'rourke Bodner & O'rourke

  
09/10/2009 > patent applications in patent subcategories. class, title,number

20090227487 - Methods for the control of macrophage-associated inflammation: Particle induced inflammatory diseases are treated by administration of an effective dose of an inhibitor of MyD88 adaptor protein.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090227488 - Class of bioactive glycoprotein: The invention relates to a bioactive chemical composition, more specifically to proteins and can be used in medicine, veterinary and cell biology. The invented glycoproteins are extracted with the help of isoelectric focusing from intercellular space of tissues taken from different organs, blood serum and bile of the vertebrates (human... Agent: Jacobson Holman PLLC

20090227489 - Stat3 agonists and antagonists and therapeutic uses thereof: The present invention relates to methods for modulating, i.e., agonizing or antagonizing, Stat3 (Signal Transducer and Activator of Transcription3) signaling activity for use in gene therapy. Inhibition and/or activation of Stat3 signaling is an effective approach to modulate angiogenesis and the immune response for treatment and/or prevention of inflammation, infection,... Agent: Fish & Richardson, PC

20090227490 - Antitumoral treatments: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.... Agent: King & Spalding

20090227491 - Antiviral phosphinate compounds: The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20090227492 - Treatment of neurological conditions using complement c5a receptor modulators: This invention relates to the treatment of neurological conditions with novel cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of C5a receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes, monocytes, lymphocytes and/or macrophages.... Agent: The Nath Law Group

20090227501 - Agents for preventing and/or treating upper digestive tract disorders: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which... Agent: Edwards Angell Palmer & Dodge LLP

20090227507 - Angiotensin (1-7) dosage forms and uses thereof: The present invention provides angiotensin (1-7) pharmaceutical compositions, dosage forms, and methods for their use, and methods for treating or limiting development of acquired immune deficiency syndrome.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090227493 - Combined drug for treating diabetes: The present invention provides a pharmaceutical composition (preferably a drug for therapeutic and/or prophylactic treatment of diabetes) comprising a GLP-1 receptor agonist and the insulin resistance improving agent 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, or a pharmacologically acceptable salt thereof, in combination.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090227500 - Genes affecting human memory performance: The present invention relates to DNA sequences associated with human memory performance. It also provides methods for (i) screening for diseases and pathological conditions affecting human memory, (ii) identifying agents useful for treatment of diseases and pathological conditions affecting human memory, and (iii) agents and compositions useful for treatment of... Agent: Foley & Lardner LLP

20090227510 - Induction of tumor immunity by variants of folate binding protein: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such... Agent: Fulbright & Jaworski, LLP

20090227502 - Juvenile hemochromatosis gene (hfe2a) cleavage products and uses thereof: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20090227494 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090227495 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090227514 - Method and composition using irvingia gabonensis for reducing body weight: Methods and compositions using plants from the Irvingiaceae family to reduce body weight in a mammal. Methods and compositions using the Irvingia gabonensis plant to reduce lipid levels, BMI and body weight, blood pressure, triglyceride levels, total amount of fat stored in the body, cholesterol levels, salivary and pancreatic alpha-amylase... Agent: Greenberg Traurig LLP (la)

20090227498 - Method of drug delivery for bone anabolic protein: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090227496 - Method of producing recombinant tat-hoxb4h protein for use as a stimulant of hematopoiesis in vivo: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090227512 - Methods and compositions for treating and preventing distal bowel lesions: This invention features compositions and methods for treating and preventing distal bowel disease by rectal administration of trefoil peptides. The trefoil peptide can be administered either alone or in combination with one or more antimicrobial agents, anti-inflammatory agents or analgesics.... Agent: Clark & Elbing LLP

20090227511 - Methods and compositions for treating lesions of the respiratory epithelium: This invention features methods of treating lesions of the airway epithelium by local or systemic administration of intestinal trefoil peptides. The intestinal trefoil peptide can be administered either alone or in combination with one or more therapeutic agents.... Agent: Clark & Elbing LLP

20090227505 - Methods and uses for protein breakdown products: Where it was generally thought that the smallest breakdown products of proteins had no specific biological function on their own, it now emerges that the body may utilize the normal process of proteolytic breakdown to generate important compounds such as gene-regulatory compounds. For instance, certain short breakdown products of hCG... Agent: Traskbritt, P.C.

20090227509 - Modulation of hiv replication by rna interference: Disclosed herein are small interfering RNAs (siRNAs), and vectors encoding one or more siRNAs (including short hairpin siRNAs), that are sufficiently homologous to a portion of the HIV genome to mediate RNA interference in vivo. Also disclosed are methods wherein siRNAs, or vectors encoding siRNAs, are administered to prevent or... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090227503 - Parathyroid hormone treatment for enhanced allograft and tissue-engineered reconstruction of bone defects: Methods of improving an outcome of a bone allograft procedure in a subject suffering from a massive bone defect are described, including providing a bone allograft to the subject and intermittently providing said subject with parathyroid hormone (PTH); where the PTH is provided in an amount effective to enhance in... Agent: Mcdermott Will & Emery LLP

20090227504 - Pegylated factor vii glycoforms: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090227508 - Peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also... Agent: Darby & Darby P.C.

20090227499 - Soluble gp130 molecule variants useful as a medicament: A polypeptide-dimer built of two identical monomeric fragments comprising the domains 1 to 3 of the extracellular (soluble) part of glycoprotein (gp)130 and a certain polypeptide spacer are described, which are covalently linked with each other and which bear significant advantages concerning their production rate in host cells, their improved... Agent: Howrey LLP-ca

20090227513 - Treating eye disorders using intestinal trefoil proteins: Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistant to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases, eye disorders and other insults.... Agent: Clark & Elbing LLP

20090227506 - Use of defensins against tuberculosis: The present invention relates to a method for killing or inhibiting cells of the genus Mycobacterium, in particular M. tuberculosis, with certain defensins.... Agent: Novozymes North America, Inc.

20090227497 - Variant activin receptor polypeptides and uses thereof: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and... Agent: Amgen Inc. Law Department

20090227515 - Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis: During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090227516 - Compound comprising an autoantigenic peptide and a carrier with a mhc binding motif: The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding... Agent: Manelli Denison & Selter

20090227517 - Myostatin binding agents: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the... Agent: Amgen Inc. Law Department

20090227518 - Compositions and methods for treating actin-mediated medical conditions: The present invention provides a method for treating a subject an actin-mediated medical condition by administering to the subject an actin modulator. In some embodiments, the actin-mediated medical condition is an intracellular actin-mediated medical condition. In other embodiments, the actin-mediated medical condition is a cellular-surface actin mediated medical condition.... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090227519 - Compounds for control of appetite: This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists... Agent: Wood, Herron & Evans, LLP

20090227520 - Treatment methods using peptides related to amyloid precursor protein: The invention provides a compound having formula X1-Arg-Xaa-Arg-X2 in which X1 and X2 are up to 30 amino acid residues and Xaa is an amino acid residue. A preferred compound is the tripeptide Arg-Glu-Arg which corresponds to amino acid residues 328 to 330 of human amyloid precursor protein. The invention... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090227521 - Use of compounds in the treatment of ischemia and neurodegeneration: TPP II (tripeptidyl peptidase II) inhibitors are useful in the treatment of a neurodegenerative disease, for example Alzheimer's, Parkinson's or Huntingdon's disease or an ischemic condition, for example stroke and cardiac infarction. Suitable compounds comprise tripeptide compounds of general formula RN1RN2N-A1-A2-A3-CO—RC1 wherein RN1, RN2, A1, A2, A3 and RC1 are... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090227522 - Targeted delivery of pharmaceutical compounds: Techniques are provided for targeting a pharmaceutically active compound using, as a carrier, a molecule (or molecules) having greater affinity for a particular site in a living organism's body than for other sites therein. A compound of the formula B-L-A is provided, where B represents the residue of a small... Agent: Ryan, Mason & Lewis, LLP

20090227524 - Antiviral therapeutic agents: c

20090227523 - Use of compatible solutes as substances having free radical scavenging properties: Methods of using compatible solutes cyclic 2,3-diphosphoglycerate (cDPG), 1,-di-glyccrol phosphate (DGP), firoin and firoin-A, and/or derivatives of these compounds or combinations thereof, for treating skin conditions such as dermatoses and age spots. The methods include the application to the skin of a cosmetic and/or dermatological preparation containing the compatible solutes.... Agent: Berliner & Associates

20090227525 - Wrinkle-diminishing agent: An antiwrinkle agent which is highly effective in alleviating wrinkles caused by the photoaging. The present invention relates to an antiwrinkle agent comprising an eugenyl glycoside.... Agent: Foley And Lardner LLP Suite 500

20090227526 - Cytoprotective composition comprising hesperidin or pharmaceutically acceptable salt thereof as an active ingredient: Disclosed is a cytoprotective composition comprising hesperidin or a pharmaceutically acceptable salt thereof as an active ingredient. Having the ability to protect cells from radiation-induced injuries in addition to being non-toxic to cells, hesperidin in accordance with the present invention can be used as an active cytoprotective agent.... Agent: Lucas & Mercanti, LLP

20090227527 - Pharmaceutical composition for preventing and/or treating bone disease, functional food or health food and pharmaceutical preparation comprising thereof as active ingredient: (In the formula (I), R1 and R5 are a functional group selected from the group consisting of a hydrogen atom, alkyl group having carbon numbers 1 to 3, monosaccharide and disaccharide; R2, R3, and R4 are a functional group selected from the group consisting of a hydrogen atom, an oxygen... Agent: Kratz, Quintos & Hanson, LLP

20090227528 - Pulmonary administration of an antithrombotic compound: The invention relates to the use of an oligosaccharide conjugated to a direct thrombin inhibitor for the manufacture of a medicament for the pulmonary delivery of said compound for the prevention or treatment of thrombosis or related disorders.... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090227529 - Combination treatment for bladder cancer: Novel methods useful for treating a patient with bladder cancer such as superficial bladder cancer includes administering to the patient a therapeutically effective amount of valrubicin and trospium chloride.... Agent: Foley And Lardner LLP Suite 500

20090227530 - Sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090227532 - Analogues of coformycin and their use for treating protozoan parasite infections: This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.... Agent: Amster, Rothstein & Ebenstein LLP

20090227531 - Transcription factors in neuronal dendrites-dendritic protein synthesis and cell death: The present invention relates to methods of altering the competence of a dendrite and/or the viability of a neuron. The present invention also provides methods of altering the ATP levels in a neuron, methods of isolating at least one protein of a mitochondrial permeability transition pore complex, methods of introducing... Agent: Kathryn Doyle, Ph.d., J.d. Drinker Biddle & Reath LLP

20090227533 - Mir-34 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-34, using miR-34 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090227657 - Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and... Agent: Ropes & Gray LLP

20090227656 - Methods for using modulators of proline-rich tyrosine kinase 2: The present invention relates to methods for preventing cell death in a subject and their application in the treatment of neurodegenerative diseases and conditions, such as Alzheimer's disease, stroke, Parkinson's disease etc. A method for preventing cell death comprises reducing or inhibiting Pyk2 activity.... Agent: Townsend And Townsend And Crew LLP

20090227654 - Modulation of neuroglia-derived bdnf in the treatment and prevention of pain: Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods an products are based on the modulation of neuroglia-derived BDNF expression or activity. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing... Agent: Schwegman, Lundberg & Woessner, P.A.

20090227655 - Nonviral vectors for delivering polynucleotides to target tissue: Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.... Agent: Pabst Patent Group LLP

20090227664 - Expression vectors able to elicit improved immune response and methods of using same: The invention relates to nucleic acids (such as DNA immunization plasmids), encoding fusion proteins containing a destabilizing amino acid sequence attached to an amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased by the presence of the destabilizing amino acid sequence.... Agent: Townsend And Townsend And Crew, LLP

20090227660 - Glp-1 gene delivery for the treatment of type 2 diabetes: This patent discloses compositions and methods of use thereof to normalize the blood glucose levels of patients with type 2 diabetes. It relates particularly to a plasmid comprising a chicken β actin promoter and enhancer; a modified GLP-1 (7-37) cDNA (pβGLP1), carrying a furin cleavage site, which is constructed and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090227662 - Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis: Compositions comprising truncated tryptophanyl-tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.... Agent: Olson & Cepuritis, Ltd.

20090227663 - Inhibition of tumor growth and invasion by anti matrix metalloproteinases dnazymes: The presently disclosed subject matter provides DNA molecules designed to down regulate the expression of MMP genes in a cell. Also provided are compositions comprising the DNA molecules. The presently disclosed subject matter further provides methods of using the DNA molecules to inhibit metastasis of a cancer cell. The presently... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090227658 - Methods and compositions for immunization against hiv: The present invention relates to nucleic acid and attenuated vaccinia vectors for prophylactic use against HIV infection, as well as methods of eliciting immune responses in subjects susceptible to HIV infection. The prophylactic vaccine regimen of the invention involves immunological priming with an inoculum comprising two novel DNA vectors, followed... Agent: Thomas J. Kowalski Frommer Lawrence & Haug

20090227659 - Nucleolar targeting of therapeutics against hiv: The HIV regulatory proteins Tat and Rev accumulate in nucleoli of human cells. No functional role has been attributed to this localization. Recently it was demonstrated that expression of Rev induces nucleolar re-localization of some nuclear factors involved in Rev export. Thus, it is likely that the nucleolus plays a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090227661 - Transcription factor decoy oligodeoxynucleotides having multiple cis elements: A double-stranded decoy oligodeoxynucleotide, the decoy oligodeoxynucleotide comprising a first strand of deoxynucleotides and a second strand of deoxynucleotides substantially complementary to the first strand of deoxynucleotides, the decoy oligodeoxynucleotide comprising at least two cis elements, each of the cis elements specifically targeting a transcription factor. Also, methods of using... Agent: Louis Tessier

20090227534 - Pharmaceutical composition comprising the combination of a ketorolac salt and vitamins of the-b-complex for the treatment of neuralgia: This invention refers to the pharmaceutical combinations of Ketorolac salts and B-complex; to the methods used to make said combinations; and particularly, to ketorolac and B-complex synergic combinations useful in the treatment of patients that suffer from moderate to severe pain and neuralgias in different body sites.... Agent: Birch Stewart Kolasch & Birch

20090227536 - Compositions comprising pectin and ascorbic acid: Ascorbic acid compositions in the form of a powder and/or granules contain as principle components L-ascorbic acid and/or a pharmaceutically acceptable salt thereof, and a high molecular (300 kDalton or higher) pectin. The compositions are compressible into tablets with improved mechanical strength and hardness.... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP

20090227535 - Process for producing natural immunobiotic extract and uses thereof: The present invention provides a process for producing β-(3-(1,3/1,6)-D-glucan from a cellular source comprising the steps of alkali extraction of the cellular source; water extraction; acid extraction; and water extraction, where at least one step of water extraction includes pasteurization by steam injection to a temperature of about 100° C.... Agent: Brinks, Hofer, Gilson & Lione

20090227537 - Sulfated polysaccharides and uses thereof in medical treatment: The invention provides sulfated oxidised regenerated cellulose compounds, sulfated alginates, and the salts and hydrates thereof. The compounds are obtained by sulfation of oxidised regenerated cellulose with sulfur trioxide. The invention also provides pharmaceutical compositions comprising the compounds, in particular compositions for the treatment of medical conditions mediated by a... Agent: Morgan, Lewis & Bockius LLP

20090227538 - N-(hetero)aryl indole derivatives as pesticides: The invention relates to compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6, A, X, m and n have the significances given in claim 1, and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites on warm-blooded... Agent: Novartis Corporate Intellectual Property

20090227539 - Boron compounds useful in bnct: The present invention relates to novel boron comprising compounds, to pharmaceutical compositions comprising said compounds, to the therapeutic use of said compounds, and to a process for preparation of said compounds. The compounds are useful in boron neutron capture therapy (BNCT).... Agent: Birch Stewart Kolasch & Birch

20090227541 - Boron-containing small molecules: This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090227542 - Novel boronic chalcone derivatives and uses thereof: The present invention relates to novel boronic chalcone derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic chalcone derivatives to... Agent: Karen B. Dow Dla Piper LLP (us)

20090227540 - Treatment of wood based on novel formulations of boratranes: A wood preservative composition comprising leach resistant boron in the form of a boratrane, and a synergistic proportion of quaternary ammonium compound. The composition can include triadimefon in synergistic proportions with the boratrane and quaternary ammonium compound. It can be in the form of a stable water dilutable composition and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090227543 - Phosphonate compounds having immuno-modulatory activity: The invention is related to phosphonate substituted compounds having immuno-modulatory activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090227544 - Bone targeted therapeutics and methods of making and using the same: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.... Agent: Swanson & Bratschun, L.L.C.

20090227545 - Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound: Methods of increasing the thickness of the epidermal layer in the skin of a human comprising topically administering a therapeutically effective dose of an active pharmaceutical ingredient comprising a vitamin D analog including 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-(24R)-1α,25-dihydroxyvitamin D2, 2-methylene-1α,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-vitamin D3, 2-methylene-(20R,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, 2-methylene-18,19-dinor-(20S)-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-19-nor-1α-hydroxy-trishomopregnacalciferol, 2-methylene-(20R)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol,... Agent: Quarles & Brady LLP

20090227546 - Pharmaceutical composition of drospirenone and ethynylestradiol: A pharmaceutical composition of drospirenone and ethynylestradiol with an improved dissolution rate. A method of preparation of a pharmaceutical formulation of drospirenone and ethynylestradiol in order to improve its dissolution profile. The formulation can be used to produce an anovulatory effect when administered correctly in humans.... Agent: Berenbaum, Weinshienk & Eason, P.c

20090227550 - Controlled release delivery system for nasal application of neurotransmitters: This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special lipophilic or partly lipophilic system of the invention leads to high bioavailability of the active ingredient in plasma and brain caused by sustained serum levels and/or direct... Agent: Frommer Lawrence & Haug

20090227549 - Fulvestrant formulations: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.... Agent: Irving M. Fishman C/o Cohent Tauber Spievack & Wagner

20090227548 - Novel glucocorticoid receptor agonists: l

20090227547 - Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative:

20090227551 - Therapeutic uses of steroidal compounds: A steroid derivative compound of formula (I) in which: one of R1 and R2 is hydroxy and the Vehicle other is hydrogen; or R1 and R2 together represent oxo; R3 is hydrogen or hydroxy; and the dotted lines represent single or double carbon-carbon bonds; and pharmaceutically acceptable salts and esters... Agent: Greenlee Winner And Sullivan P C

20090227552 - Fulvestrant formulations: The present invention relates to novel fulvestrant formulations comprising one or more of a propylene glycol or a pharmaceutically acceptable polyethylene glycol.... Agent: Winston & Strawn LLP Patent Department

20090227553 - Synthesis of chlorins and phorbines with enhanced red spectral features: The present invention provides compounds of the general Formula DI: along with methods of making such compounds, formulations containing the same, and methods of using the same (e.g., in photodynamic therapy, for the production of solar cells, etc.)... Agent: Myers Bigel Sibley & Sajovec

20090227554 - Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens: Provided are methods of determining a resistance-adjusted dosage regimen of an anti-infective agent for treatment of an infection of a mammal by a resistant infective organism, wherein an effective dosage regimen of the anti-infective agent is known for treatment of an infection of the mammal by a susceptible strain of... Agent: Fox Rothschild, LLP Elan Pharma International Limited

20090227557 - Substituted beta-lactams: o

20090227559 - Snps in the apob gene and susceptibility to increased levels of alat following ximelagatran administration: This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the apoB gene and susceptibility to increased... Agent: Astrazeneca R&d Boston

20090227561 - Fused heterocyclic derivative and use thereof: wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090227560 - Substituted imidazole compound and use thereof: e

20090227558 - Amino-derivatives as novel inhibitors of histone deacetylase:

20090227556 - Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives: [R1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents a 3- to 10-membered... Agent: Birch Stewart Kolasch & Birch

20090227555 - Novel pyridine compounds: The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, and processes for their preparation, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20090227562 - Combination of a selective noradrenaline reuptake unhibitor and a pdev inhibitor: The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phospho-diesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain.... Agent: Pharmacia Corporation Global Patent Department

20090227563 - Herbicidal compositions having improved effect: The present invention concerns boosting the activity of crop protection materials comprising active ingredients from the class of the phenyl-substituted cyclic ketoenols through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them,... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090227564 - Drug for prevention and/or therapy of endometriosis: A drug effective for prevention and therapy of endometriosis is disclosed. The drug for prevention and/or therapy of endometriosis according to the present invention comprises an antiallergic agent as an effective ingredient.... Agent: Birch Stewart Kolasch & Birch

20090227565 - Biphenyl vasopressin agonists: d

20090227566 - Aromatic ether derivatives useful as thrombin inhibitors: This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example... Agent: Eli Lilly & Company

20090227567 - Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors: i

20090227568 - Methods and compositions for the delivery of a therapeutic agent: The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods... Agent: Goodwin Procter LLP Patent Administrator

20090227569 - Pyrrolidine derivatives: Pyrrolidine compounds described herein and methods for using them to inhibit dipeptidyl peptidase IV and treat Type II diabetes.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090227570 - 2-aminoquinolines: r

20090227571 - Androgen receptor modulator compounds and methods: Provided herein are compounds that bind to androgen receptors and modulate the activity and/or the amount of androgen receptors and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.... Agent: K&l Gates LLP

20090227572 - Treatment of diabetic wounds and peripheral neuropathies: The present invention provides methods of enhancing healing of wound associated with diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. In another aspect, the instant invention provides methods of treating or preventing peripheral nervous system neuropathies. Peripheral nervous... Agent: Ropes & Gray LLP

20090227573 - Substituted cyclopentanes having prostaglandin activity: e

20090227575 - 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis:

20090227574 - Administration of carboline derivatives useful in the treatment of cancer and other diseases: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of those compounds. provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor... Agent: Jones Day

20090227576 - 2-alkylbenzoxazole carboxamides as 5ht3 modulators:

20090227577 - Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer: The invention relates to compounds of formula I, wherein Ra is —C(O)ORI, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either Q is optionally substituted by Rba and/or Rbb... Agent: Millen, White, Zelano & Branigan, P.C.

20090227578 - Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents: e

20090227579 - Pteridine derivatives and their use as cathespin inhibitors: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin K.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090227581 - 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to novel 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of β-secretase, also known as β-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or... Agent: Philip S. Johnson Johnson & Johnson

20090227584 - 2-aminoquinoline derivatives: wherein R1 and R2 are as described herein, pharmaceutical compositions containing such compounds, and methods for their manufacture. The compounds of the invention are 5-HT5A receptor antagonists useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090227583 - 2-aminoquinolines: wherein A, R1, R2, R3, R4, and R5 are as described herein, pharmaceutical compositions containing them, and methods for their manufacture. These compounds are 5-HT5A receptor antagonistsand are useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090227580 - Bicyclic derivatives as cetp inhibitors: e

20090227582 - Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic... Agent: The Firm Of Hueschen And Sage

20090227585 - Substituted n-heterocycle derivatives and methods of their use: The present invention is directed to substituted N-heterocycle derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and... Agent: Wyeth Patent Law Group

20090227586 - 2-anilino-4-(heterocyclic)amino-pyrimidines: The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090227587 - Pyrimidines as inhibitors of phosphoinositide-3-kinases (pi3k): wherein R4, R6, and Y have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds of... Agent: Pfizer Inc

20090227588 - Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090227589 - Pyrazole derivatives as sigma receptors antagonists: s

20090227590 - Quaternary ammonium salts as m3 antagonists: Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090227592 - Compounds effecting glucokinase: m

20090227591 - Cyclopentene compounds:

20090227593 - Cyclobutyl amine derivatives:

20090227594 - Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090227595 - Glycine transporter-1 inhibitors: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also... Agent: Amgen Inc.

20090227596 - Heteroaryl nitrile derivatives: e

20090227597 - Pyrazolopyrimidinones as phosphodiesterase inhibitors: Compounds of formula (I) wherein R1 is H, C1-C3-alkyl, C3-C5-cycloalkyl or C1-C3-perfluoroalkyl, R2 is H, C1-C6-alkyl optionally substituted by OH, C1-C3-alkoxy or C1-C3-perfluoroalkyl, R3 is C1-C6-alkyl, C3-C6-alkenyl, C3-C6-alkinyl, C3-C7-cycloalkyl, C1-C6-perfluoroalkyl or C3-C6-cycloalkyl-C1-C6-alkyl, R4=H, ADT-OH, cysteine, agmatine, arginine, aminoguanidine or agents releasing or stimulating the release of hydrogen sulfide, and salts... Agent: Schneck & Schneck

20090227598 - Ret tyrosine kinase inhibition: The present invention provides methods for inhibiting RET tyrosine kinase. Further, the present invention also provides methods of treating or preventing thyroid cancer.... Agent: Merck And Co., Inc

20090227599 - Sulfonyl-substituted bicyclic compounds as modulators of ppar: Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: Global Patent Group - Kal

20090227600 - 4-(pyrazine-2-yl) -pyrrolidine -2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors: A represents hydroxy; B represents C(O)R3 wherein R3 is 4-tert-butyl-3-methoxyphenyl; D represents 1,3-thiazol-2-yl or 5-methyl-1,3-thiazol-2-yl; E represents pyrazin-2-yl; G represents 1,3-thiazol-2-ylmethyl, 1,3-thiazol-4-ylmethyl, 1,2-thiazol-3-ylmethyl, or 1H-pyrazol-1-ylmethyl; and salts, solvates and esters thereof; provided that when A is esterified to form —OR where R is selected from straight or branched chain alkyl,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090227601 - Bradykinin 1 receptor antagonists: The invention encompasses novel compounds and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for treatment of diseases mediated by B1 bradykinin receptor.... Agent: Amgen Inc.

20090227602 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38αMAP kinase and/or HMG-CoA reductase, as well as... Agent: Wilson Sonsini Goodrich & Rosati

20090227603 - Leukotriene b4 inhibitors: e

20090227604 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.... Agent: Eli Lilly & Company

20090227605 - Enhanced efficacy benzisoxazole derivative dosage forms and methods: Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that provide enhanced efficacy when used in the treatment of schizophrenia and/or bipolar mania.... Agent: Philip S. Johnson Johnson & Johnson

20090227606 - Methods for preventing or treating acute and chronic pain: The present invention is a method for preventing or treating acute and chronic pain. Using an agent to increase the expression or activity of GLT-1, behavioral hypersensitivity is attenuated thereby preventing or treating acute and chronic pain in a subject in need of such treatment. Methods for identifying agents that... Agent: Licata & Tyrrell P.C.

20090227607 - Deazapurines useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20090227608 - Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the... Agent: Novartis Corporate Intellectual Property

20090227609 - Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agents: The present invention concerns novel amidines derivatives of 2-heteroaryl-quinazoline and quinolines of general formula (I), to a process for their preparation, to their pharmaceutical compositions and to the use of these compounds, salts and solvates thereof, along with the corresponding pharmaceutical compositions, for the treatment of pain and inflammatory disorders.... Agent: Sughrue Mion, PLLC

20090227612 - Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same: A compound of formula 1 efficiently inhibits several protein kinases including glycogen synthase kinase 3 (GSK), aurora kinase, extracellular signal-regulated kinase (ERK), protein kinase B (AKT), and the likes, to control signal transductions involved in variable disorders such as diabetes, obesity, dementia, cancer, and inflammation.... Agent: Sughrue Mion, PLLC

20090227611 - Crystal form of phenylamino pyrimidine derivatives: The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans. The compound of formula I, also known as AN-019, is:... Agent: Merchant & Gould PC

20090227610 - Novel triglyceride reducing agent: The present invention relates to hypotriglyceridemic agent containing HMG-CoA reductase inhibitor and cAMP protease inhibitor.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090227614 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarnic receptors of formula (I). The present invention also provides impositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Honigman Miller Schwartz & Cohn LLP

20090227613 - Novel 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20090227615 - Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.... Agent: Davidson, Davidson & Kappel, LLC

20090227617 - Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy: The invention relates to novel esters and in particular to some novel esters of glucuronide prodrugs of anthracyclines having tunable water-solubility, their synthesis and use in tumor-selective chemotherapy. It appeared that in the final step in the synthesis of these prodrugs, i.e. the coupling of the glucuronide spacer moiety to... Agent: Troutman Sanders LLP Bank Of America Plaza

20090227616 - Inhibitors of akt activity: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090227618 - Carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy... Agent: Jones Day

20090227619 - Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo: This invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally... Agent: Weaver Austin Villeneuve & Sampson LLP

20090227620 - Anti-inflammatory compounds: The use of a steroid sulfatase inhibitor in the preparation of a medicament for the treatment of inflammatory diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090227622 - Imidazo[1,2-a]pyridine compounds as vegf-r2 inhibitors: The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.... Agent: Eli Lilly & Company

20090227621 - Naphthyridine derivatives having inhibitory activity against hiv integrase: R4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090227623 - Deuterium-enriched palosetron: The present application describes deuterium-enriched palonosetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090227624 - Oxazole and thiazole compounds as beta-catenin modulators and uses thereof: e

20090227625 - Cxcr2 inhibitors: in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090227628 - 2-aminoquinolines: wherein Z, R1, and Ar1 are as defined herein, pharmaceutical compositions containing them, methods for their manufacture. The compounds are 5-HT5A receptor antagonists and are useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090227627 - 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace): The present invention is directed to 6-substituted-thio-2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of β-secretase, also known as β-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.... Agent: Philip S. Johnson Johnson & Johnson

20090227626 - Novel polyquinoline derivatives and therapeutic use thereof: The invention relates to compounds of general formula (I), to the process for the preparation thereof and to the use thereof as a therapeutic agent.... Agent: Young & Thompson

20090227629 - Compounds having activity at the glycine transporter glyt1 and uses thereof: e

20090227630 - Pharmaceutical composition achieving excellent absorbency of pharmacologically active substance: The present invention provides a pharmaceutical composition that can efficiently achieve its medicinal action by having excellent basic pharmacologically active substance absorbency, even the basic pharmacologically active substance is poorly soluble, the pharmaceutical composition being prepared by adding (i) a basic pharmacologically active substance together with (ii) a fatty acid... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090227631 - 2-adamantylurea derivatives as selective 11beta-hsd1 inhibitors: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Millen, White, Zelano & Branigan, P.C.

20090227632 - Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin reuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor: A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts there and at least one second active ingredient chosen from selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors and pharmaceutically acceptable salts thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090227633 - Methods to inhibit tumor cell growth by using proton pump inhibitors: Methods of treating one or more growth deregulated cells are disclosed. An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a growth deregulated cell outside of the gastric lumen of a subject.... Agent: Traskbritt, P.C.

20090227634 - Pyrazole derivatives as 5-lo-inhibitors: t

20090227635 - Therapeutic compounds:

20090227636 - Therapeutic compounds:

20090227637 - Diaryl ureas for treating virus infections: The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.... Agent: Millen, White, Zelano & Branigan, P.C.

20090227639 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090227638 - Novel pharmaceutical compounds: The instant invention provides compounds of Formula (Ia) which are leukotriene biosynthesis inhibitors, wherein X is O or S, Y is O, S, —NR6—CHR7— or —NR8—C(O)— and A is selected from 5-membered aromatic heterocyclic ring, 6-membered aromatic heterocyclic ring, naphthelenic or heterobicyclic aromatic ring system, phenyl and benzyl. A is... Agent: Merck And Co., Inc

20090227641 - Cycloalkylamino acid derivatives: e

20090227640 - Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases: The present application relates to novel heterocyclic compounds, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20090227642 - Novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production: The present invention provides a method for the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica comprising administering a therapeutically effective amount of (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090227643 - Novel salts of substituted 5-membered azacycle and use thereof in the treatment of diseases related to protein aging: The present invention relates to 5-membered azacycle compounds of formula (I), pharmaceutically acceptable salts thereof and hydrates thereof, wherein the groups are as defined in the specification. The present invention further relates to pharmaceutical compositions containing said compounds or pharmaceutically acceptable salts thereof or hydrates thereof, and to use of... Agent: Harness, Dickey & Pierce, P.L.C

20090227644 - Agent for regeneration and/or protection of nerves: An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet... Agent: Sughrue-265550

20090227645 - Pharmaceutical compositions of valdecoxib: The present invention relates to novel crystalline forms of valdecoxib, to processes for their preparation and to pharmaceutical compositions containing them.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090227646 - Compositions comprising nebivolol: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular... Agent: Frost Brown Todd, LLC

20090227647 - Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of IAPP or amylin fibril diseases, and the manufacture of medicaments for such treatment.... Agent: Proteotech, Inc.

20090227649 - Management of ophthalmologic disorders, including macular degeneration: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20090227648 - Pyrazole derivatives useful for the treatment of cancer: This invention relates to novel compounds having the formula and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.... Agent: Astrazeneca R&d Boston

20090227650 - Novel crystalline forms of lestaurtinib: Novel crystalline forms of lestaurtinib are described, including six co-crystal forms, nineteen solvate forms, three anhydrate forms and one hemihydrate form. Methods of their preparation and use are also described.... Agent: Ross J. Oehler Cephalon, Inc.

20090227652 - Indole derivatives and methods of using the same: The invention provides indole-4,7-dione derivatives useful for the treatment of diseases in a mammal, pharmaceutical compositions containing the same and methods of using the same in the treatment of cancer and neoplastic diseases including human solid tumors and other mammalian tumors.... Agent: Sheridan Ross PC

20090227651 - Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction: e

20090227653 - Substituted gamma lactams as therapeutic agents:

20090227666 - Enhancing disease resistance in an animal: A method to enhance disease resistance in an animal comprising feeding the animal a diet enriched in antioxidants and providing behavioral enrichment. In one embodiment, the behavioral enrichment comprises exercising the animal regularly effective to cause behavioral enrichment, wherein the feeding and exercising combination is effective to increase neutrophil phagocytosis... Agent: Colgate-palmolive Company

20090227665 - Methods and compositions for the prevention and treatment of kidney disease: The invention provides compositions for preventing or treating kidney disease and improving kidney function comprising at least two ingredients selected from the group consisting of antioxidants and mitochondrial cofactors in amounts sufficient for preventing or treating kidney disease or for improving kidney function and methods for preventing and treating kidney... Agent: Colgate-palmolive Company

20090227667 - Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof: are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused... Agent: Howson & Howson LLP / Wyeth

20090227668 - Topical application of ivermectin for the treatment of dermatological conditions/afflictions: Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective... Agent: Buchanan, Ingersoll & Rooney PC

20090227669 - Compositions and methods for perioperative bladder instillation: Polyphenol- and especially catechin-containing compositions (e.g., Polyphenon E) are instilled in the bladder of a subject that previously underwent surgical resection or removal of bladder cancer to reduce cancer growth and/or recurrence.... Agent: Fish & Associates, PC Robert D. Fish

20090227670 - Pharmaceutical compositions comprising flavonoids and menthol: The present invention relates to use of certain antiviral fragrances for reduction of viruses, in particular vira causing common cold. In one embodiment, the invention relates to pharmaceutical compositions comprising an antiviral fragrance, preferably menthol. Said compositions preferably also comprise one or more flavonoids. The invention also relates to treatment... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090227671 - Prevention and treatment of atherosclerosis with lithospermate b: This invention relates to lithospermate B (‘LAB’ hereinafter) that inhibits proliferation and migration of vascular smooth muscle cells (‘VSMC’ hereinafter). More specifically, this invention relates to a pharmaceutical composition comprising LAB isolated from Salviae miltiorrhiza as an active ingredient for treating atherosclerosis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090227672 - Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular... Agent: Allergan, Inc.

20090227673 - Method and composition for the treatment of parkinson's disease: It has been discovered that polyphenols are effective as a co-pharmaceutical in combination with traditional dual drug therapies of catecholamines and decarboxylase inhibitors for the treatment of Parkinson's disease. Accordingly, a method of treating Parkinson's disease comprising administering to a subject suffering from Parkinson's disease a pharmaceutical composition comprising at... Agent: Nelson Mullins Riley & Scarborough, LLP

20090227674 - Combination methods fo saha and targretin for treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of SAHA or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of Targretin. The SAHA and Targretin may be administered... Agent: Merck And Co., Inc

20090227675 - Antimicrobial compositions: Antimicrobial compositions which are active against bacteria, yeast and mold spores are described. The compositions may be blends of (I) an acrylate/methacrylate copolymer having a hydrophobic network structure and (II) a preservative component comprising comprising (A) an isothiazolinone or (B)phenoxyethanol and either (i) a 1,2-diol or (ii) benzoic acid and... Agent: International Specialty Products William J. Davis, Esq.

20090227676 - Methods and compositions for treating cancer: Pharmaceutical compositions and kits useful for the treatment of cancer include certain alkyl esters of cystine and certain alkyl-substituted cystamine derived esters, including, for example, cystine dimethyl ester and a di-alkyl peptidyl cystamine ester, among others. These compounds may be employed in methods of treating cancers or methods of determining... Agent: Howson & Howson LLP

20090227677 - Low dose lipoic acid pharmaceutical compositions and methods: Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, and lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases.... Agent: Townsend And Townsend And Crew, LLP

20090227678 - Process for obtaining lipid form cells: The present invention relates to a process for obtaining lipid from a composition comprising cells and water, said process comprising contacting the composition with a desiccant, and recovering the lipid from the cells. The invention also relates to a lipid obtainable by this process. The process according to then invention... Agent: Nixon & Vanderhye, PC

20090227679 - Novel niddm regimen: The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090227680 - Amino acid derivatives: The present invention relates to a method of treating pain using a compound of formula (I), wherein Ar, R1, R3 and R3a are as defined herein. The invention also relates to certain novel compounds of formula (I).... Agent: Pfizer Inc. Patent Department

20090227681 - Polymorphic form of n-(s)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl) cyclopropane-1-sulfonamide and uses thereof: Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N—(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.... Agent: Wilson Sonsini Goodrich & Rosati

20090227682 - Xetine compositions: The invention provides a xetine or salt thereof composition having a dissolution in a phosphate buffer at pH 6.8, using USP basket 10 Mesh at 75 rpm, of at least 15% at 60 minutes, of at least 40% at 120 minutes, of at least 70% at 300 minutes.... Agent: Harness, Dickey & Pierce, P.L.C

20090227683 - Compositions for providing an analgesic effect to the skin: wherein R1, R2, R3, R4 and R5 independently are selected from the group consisting of hydrogen, C1-C6 alkyl, and C1-C6 hydroxyalkyl; or a cosmetically-acceptable salt thereof, and a sensation-blocking agent, where the compositions provide an analgesic effect to the skin when applied to an area of skin exhibiting at least... Agent: Philip S. Johnson Johnson & Johnson

20090227684 - Glutaraldehyde composition: This invention relates to a stabilised aqueous glutaraldehyde solution including 0.005% to 45% m/v, suitably 10% to 45% m/v solution of glutaraldehyde, an alcohol ethoxylate non-ionic surfactant, a buffer and a sufficient amount of a pH modifier to bring the pH of the solution to 6.0 to 8.5. The glutaraldehyde... Agent: Pauley Petersen & Erickson

20090227685 - Substituted hydrogenated naphthalene derivatives and their use in fragrance formulations: wherein R is hydrogen, a straight, branched or cyclic hydrocarbon moiety consisting of less than 10, most preferably less than 4 carbon atoms and containing single and/or double bonds, an acetyl group and substituted acetyl groups including cyclic groups, such as cyclopropyl acyl group, alkoxy ether groups and alkyl substituted... Agent: International Flavors & Fragrances Inc.

20090227686 - Methods of preventing, treating and diagnosing disorders of protein aggregation: Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20090227687 - Pediculicide/ovicide composition: The present invention relates to a pediculicide/ovicide composition and method of use thereof. In particular, the present invention relates to a pediculicide/ovicide composition comprising a sesquiterpene alcohol and a suitable carrier.... Agent: Frommer Lawrence & Haug

20090227688 - Admixture of carotenoids having provitamin a activity and carotenoids devoid of provitamin a activity for treating aging symptoms: Intimate admixtures of at least one carotenoid having provitamin A activity and at least one carotenoid devoid of provitamin A activity are well suited for treating the undesirable cutaneous signs of skin aging, in particular the determination of the skin and/or of the mucous membranes by inhibiting the activity and/or... Agent: Buchanan, Ingersoll & Rooney PC

20090227689 - Low-swelling biocompatible hydrogels: Some aspects of the present disclosure relate to methods for treating a tissue by forming a low-swelling biodegradable hydrogel in situ adherent to the tissue. In embodiments the hydrogel exhibits negative swelling, i.e., shrinking. Such treatments may be utilized to in cosmetic or reconstructive surgery, in sphincter augmentation, treating nerve... Agent: Tyco Healthcare Group Lp

20090227690 - Cyclodextrin inclusion complexes and methods of preparing same: Cyclodextrin inclusion complexes and methods for preparing cyclodextrin inclusion complexes. In some embodiments, the method for preparing a cyclodextrin inclusion complex may include dry blending cyclodextrin and an emulsifier to form a dry blend, and combining a solvent and a guest with the dry blend to form a cyclodextrin inclusion... Agent: Michael Best & Friedrich LLP

20090227691 - Method for releasing molecule of interest based on target nucleic acid sequence: It is an object of the present invention to provide a method for highly selectively releasing a molecule of interest such as an agent at a desired site while suppressing the influence of catabolic enzymes existing in vivo. The present invention provides a method for releasing a molecule of interest,... Agent: Greenblum & Bernstein, P.L.C

20090227692 - Biomarkers for breast cancer: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.... Agent: Edwards Angell Palmer & Dodge LLP

  
09/03/2009 > patent applications in patent subcategories. class, title,number

20090221468 - Autonomously replicating kshv cis-acting elements: This invention provides methods of reducing a replication of a gammaherpesvirus genome, treating a KSHV infection, and treating or reducing an incidence of a KSHV-associated disease, comprising contacting a subject with a composition that inhibits initiation of DNA replication from a region of a genome of a gammaherpesvirus. The invention... Agent: Pearl Cohen Zedek Latzer, LLP

20090221469 - Use of soy kefir powder for reducing pain, blood pressure and inflammation: The present invention relates to a soy kefir powder produced by the fermentation of soy milk with Kefir grains of the Moscow strain under suitable fermentation conditions. The soy kefir powder of the invention has at least one of the following biological activities: pain relief, blood pressure reduction and inflammation... Agent: Darby & Darby P.C.

20090221471 - Prodrugs of vancomycin with hydrolysis resistant polymer linkages: Vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are hydrolysis resistant in vitro, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed.... Agent: Lucas & Mercanti, LLP

20090221470 - Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent: This invention is directed to methods of administering an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The invention is also directed to methods of using an echinocandin antifungal agent in combination with a specified glycopeptide antibacterial agent... Agent: Theravance, Inc.

20090221472 - Method for treating transplant rejection: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need... Agent: Clark & Elbing LLP

20090221473 - Antitumor agents: Compounds and methods useful for the treatment of cancer in subjects in need of such treatment. The compounds are metabolites of the compound FK228 which have been identified as possessing HDAC inhibitory activity and anticancer properties. Further provided are compounds and methods for inducing apoptosis in cancer cells. Further provided... Agent: Calfee Halter & Griswold, LLP

20090221474 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090221496 - novel antithrombotic agent: The present invention provides: a pharmaceutical composition comprising an albumin conjugated with polyethylene glycol; and a method of treating a human thrombosis or a human ischemic disease, comprising intravenously administering an albumin conjugated with polyethylene glycol to a patient.... Agent: Darby & Darby P.C.

20090221483 - Antimicrobial cathelicidin peptides: The invention relates to antimicrobial cathelicidin polypeptides related to a 38 amino acid peptide having SEQ ID NO:4. The invention provides for polypeptides having broad spectrum antimicrobial activity, nucleic acids and expression vectors encoding such polypeptides, as well as host cells and methods of reducing survival of a microbe. In... Agent: Schwegman, Lundberg & Woessner, P.A.

20090221488 - Certain compositions and methods of treatment: Disclosed inter alia is the use of certain chromenone derivatives, which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The chromenones derivatives are administered with another chemotherapeutic agent selected from neutropenia treatment agents, alkylating agents, antimetabolites, platinating agents, topoisomerase inhibitors, tubulin agents... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090221504 - Dose of an angiogenic factor and method of administering to improve myocardial blood flow: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it... Agent: Alston & Bird LLP

20090221490 - Endothelin receptors in morphine withdrawal: The present invention relates to compositions and methods for managing opioid tolerance and reducing opioid withdrawal. More specifically, the present invention provides for endothelin, endothelin receptors, and endothelin receptor antagonists and agonists as a means for managing G-protein activity in the context of opioid tolerance and withdrawal.... Agent: Dewey & Leboeuf LLP

20090221492 - Expression of active human factor ix in mammary tissue of transgenic animals: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090221497 - Immunodynamic complexes and methods for using and preparing such complexes: The present invention is directed to immunodynamic complexes that, in embodiments of the invention, are surprisingly antimicrobial and immunoactive. By “immunoactive,” it is meant that such compositions are capable of modulating, stimulating and repairing the immune system. Moreover, in embodiments of the invention, an immunodynamic complex is capable of supporting,... Agent: Covington & Burling, LLP Attn: Patent Docketing

20090221480 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090221479 - Lgi, lingo and p75ntr family members: novel modulators of neuronal growth: The present invention relates to a novel method to promote regeneration or repair of the central or peripheral nervous system following injury The present invention concerns the use of a leucine-rich, glioma-inactivated protein (LGIn), or an analog or derivative thereof, to promote the regeneration or remyelination of neurons after injury... Agent: Ogilvy Renault LLP

20090221477 - Linkers: We disclose therapeutic polypeptides comprising at least two domains capable of binding to a cytokine receptor, wherein the domains are connected by a peptide linker, wherein the linker optionally comprises a rigid alpha helical region.... Agent: Crowell & Moring LLP Intellectual Property Group

20090221499 - Lipidating sequences and use thereof for producing lipidated proteins in e. coli: Production in E. coli of a lipidated fusion protein containing a lipidating sequence derived from Ag473 and a target polypeptide.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090221486 - Method for treating and/or preventing infections in infants delivered via caesarean section: The present invention provides the use of a composition comprising uronic acid oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090221494 - Method of modulating cellular activity and agents for use therein: The invention provides a method for improving airway conductance in a subject in need thereof, the method comprising administering to the subject an effective amount of one or more of tumstatin; a derivative, variant or homologue thereof, a polynucleotide encoding tumstatin or a derivative, variant or homologue thereof; or an... Agent: Knobbe Martens Olson & Bear LLP

20090221501 - Mixing and matching tc proteins for pest control: The subject invention relates to the surprising discovery that toxin complex (TC) proteins, obtainable from Xenorhabdus, Photorhabdus, and Paenibacillus, can be used interchangeably with each other. In particularly preferred embodiments of the subject invention, the toxicity of a “stand-alone” TC protein (from Photorhabdus, Xenorhabdus, or Paenibacillus, for example) is enhanced... Agent: Jay M. Sanders Saliwanchik, Lloyd & Saliwanchik

20090221500 - Modified toxins: The present application relates to compositions of modified toxins exhibiting reduced immunogenicity and reduced binding to vascular endothelium or vascular endothelial cells, thereby reducing the incidence of Vascular Leak Syndrome. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue... Agent: Wilson Sonsini Goodrich & Rosati

20090221478 - Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases: Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090221493 - Ocl-2a3 compositions and uses thereof: This invention relates to osteoclast-specific gene and proteins. Specifically, the invention relates to OCL-2A3 or Atp6v0d2, the gene encoding it and uses thereof in methods and treatment of bone disorders.... Agent: Pearl Cohen Zedek Latzer, LLP

20090221485 - Oral peptides conjugates for metabolic diseases: The present invention relates to the field of metabolic compound conjugates, methods of forming said conjugates and uses of these conjugates in the treatment of diabetes and conditions related to this condition. The metabolic compound conjugates of this invention include a metabolic peptide having a glucagon-like peptide (GLP-1) receptor binding... Agent: Moore & Van Allen PLLC

20090221476 - Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.... Agent: Foley And Lardner LLP Suite 500

20090221487 - Polyethlene glycol modifications of thymosin alpha-1: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.... Agent: Alston & Bird LLP

20090221491 - Purification and use of a factor for supporting wound healing: A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth factor (PDGF), Epidermal growth factor (EGF), transforming growth factor alfa (TGF-α), Transforming growth factor beta (TGF-β), insulin like growth factor (IGF-1) and... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090221481 - Stimulatory auto-antibodies to the pdgf receptors as pathology marker and therapeutic target: An in vitro method for detecting the presence in a body sample of auto-antibodies for the PDGF receptor suitable for the diagnosis and prognosis of autoimmune diseases, in particular the systemic sclero-is and related diagnostic kits. Use of an inhibitor of ROS and/or Ras-ERK1/2 for the preparation of a medicament... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090221482 - Tissue protective peptides and uses thereof: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin... Agent: Jones Day

20090221495 - Treatments for neurological disorders: Disclosed are methods of improving impaired proprioception, treating brachial plexus injuries, regenerating large and small nerve fibers, treating dorsal root nerve injuries, and improving sensory neural responses in a subject by administration of a neublastin polypeptide.... Agent: Fish & Richardson

20090221484 - Use of factor vii polypeptides for neuroprotection: New methods and compositions for providing neuroprotection in gyrencephalic mammals comprising a neuroprotective dose of Factor Vila or a neuroprotective Factor Vila equivalent are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090221498 - Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications: The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090221503 - Use of rapamycin and rapamycin derivatives for the treatment of bone loss: The present invention relates to a new use of rapamycin and rapamycin derivatives.... Agent: Novartis Corporate Intellectual Property

20090221502 - Vegetarian anabolic protein composition: Vegetarian amino acid sources are combined to create a protein blend that closely matches human muscle tissue in terms of amino acid composition. “Closely matching” means that the amino acid composition of the protein blend is within five percent (5%) of the amino acid composition of human muscle for all... Agent: Gabor L. Szekeres

20090221489 - Water-soluable films comprising low-viscosity alginates: A film comprising as a film-forming agent an alginate salt of monovalent cation or a mixture of alginate salts containing at least one alginate salt of monovalent cation, the film-forming agent being such that a 10% aqueous solution thereof at a temperature of 20° C. has a viscosity of 100-1000... Agent: Ladas & Parry LLP

20090221507 - Compositions and methods for treating nervous system disorders: The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.... Agent: Spencer Fane Britt & Browne LLP

20090221505 - Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a... Agent: Fulbright & Jaworski L.L.P.

20090221506 - Gdnf derived peptides: The present invention relates to peptide fragments derived from the proteins belonging to the TGFbeta superfamily, pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090221508 - Immunomodulatory and anti-tumour peptides: The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKKYKGKFW, showing aminoacids substitutions, these peptides unable to bind to the lipopolysaccharide and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.... Agent: Hoffmann & Baron, LLP

20090221509 - Tumour-associated peptides binding to mhc-molecules: The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090221510 - Erythropoietin receptor peptide formulations and uses: The present invention relates to novel uses of peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to methods of using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production, including chemotherapy induced anemia. Pharmaceutical compositions, which comprise the... Agent: Fulbright & Jaworski L.L.P.

20090221511 - Trpv1 + sensory neurons control of beta-cell stress and islet inflammation in diabetes: A process is disclosed for controlling inflammatory tissue access through release of neuropeptides, such as substance P (sP), to insulin-responsive sensory neurons, whereby simultaneous control of insulin sensitivity/resistance is manifested. In models of Type 1 and Type 2 diabetes, sensory afferents, in particular TRPV1, have fundamental roles in insulin/glucose homeostasis,... Agent: Vedder Price, PC

20090221512 - Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms... Agent: Hoffmann & Baron, LLP

20090221514 - Methods for prevention and treatment of acute renal injury: The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an... Agent: Foley & Lardner LLP

20090221513 - Treatment of neurodegenerative disorders: Peptides having the sequence D-Arg-L-Glu-L-Arg, or the sequence L-Arg-D-Glu-L-Arg and derivatives thereof, are disclosed. Such peptides are useful in treatment of neurodegenerative disorders, and as cognitive enhancers. Preferred peptides include a protective group.... Agent: Wolf Greenfield & Sacks, P.C.

20090221515 - Monosaccharide derivatives: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis,... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090221516 - Novel glycolipid and use thereof: The compound of the present invention and a salt thereof can preferentially induce production of IL-4, which is one kind of cytokines that control action of immunocytes. Therefore, it is useful for the prophylaxis or treatment of autoimmune diseases, infectious diseases and the like, and prophylaxis or treatment of diseases... Agent: Leydig Voit & Mayer, Ltd

20090221517 - Biologically active compounds: Compounds having useful biological activity, particularly antioxidant and anti-inflammatory activity, derived from Centipeda cunninghamii, and biologically active derivatives thereof, pharmaceutical compositions comprising these compounds, and prophylactic and therapeutic use of the compounds.... Agent: The Nath Law Group

20090221519 - Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound: This invention relates to combinations of an abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to α1-acidic glycoprotein (AGP), as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to inhibition of abl-, PDGF-Receptor- and/or Kit-receptor tyrosine kinase. In... Agent: Novartis Corporate Intellectual Property

20090221518 - Compositions and methods for treatment of exudative serous effusion: Compositions and methods are provided for treating accumulation of exudative serous effusions caused by illnesses such as cancer, infection, and pancreatitis. In one embodiment, the method of the invention comprises administering to such mammal a macrolide in an amount effective to prevent or at least alleviate said exudative serous effusion... Agent: David P. Lentini

20090221520 - Polyene antibiotics, compositions containing said antibiotics, method and micro-organisms used to obtain same and applications thereof: The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl C1-C3; and R2 represents a functional group selected from CH3— or CONH2— (methyl- or primary amide-). The aforementioned polyenes have a biocide action on organisms comprising cell membranes that contain ergosterol, e.g., fungi or parasites. Said compounds... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090221672 - Biomarker for prostate cancer: The present invention provides a protein-based biomarker, Protein C Inhibitor (PCI) that is useful in qualifying prostate cancer status in a patient. In particular, the biomarker of this invention is useful to classify a subject sample as prostate cancer or non-prostate cancer. The biomarker can be detected by SELDI mass... Agent: Edwards Angell Palmer & Dodge LLP

20090221673 - Compositions and methods for regulating rna translation via cd154 ca-dinucleotide repeat: Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154.... Agent: Licata & Tyrrell P.C.

20090221674 - Compositions and methods for therapy and diagnosis of cancer: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating... Agent: Mcandrews Held & Malloy, Ltd

20090221678 - Compositions and methods for treatment of prostate and other cancers: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for... Agent: Larson & Anderson, LLC

20090221676 - Glucose-transport related genes, polypeptides, and methods of use thereof: Methods and compositions for modulating glucose transport are provided herein.... Agent: Fish & Richardson PC

20090221670 - Method for diagnosis and treatment of a mental disease: The present invention relates to association of one or more polymorphisms located in the human NHP2L1, PACSIN2, SERHL, PIPPIN, BRD1, EP300, FAM19A5 and/or GPR24 genes to the occurrence of schizophrenia and/or bipolar disorder. The invention relates both to methods for diagnosing a predisposition to said diseases and for treating subjects... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090221677 - Methods for reducing body fat and increasing lean body mass by reducing stearoyl-coa desaturase 1 activity: It is disclosed here that inhibiting the activity of the enzyme stearoyl-CoA desaturase (SCD1) in an animal causes the animal to have less body fat and greater lean body mass. The lower of SCD1 activity level can be accomplished by inhibiting activity of the enzyme or lowering levels of active... Agent: Nicholas J. Seay Quarles & Brady LLP

20090221671 - Modulation of lmw-ptpase expression: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are... Agent: Mcdermott Will & Emery

20090221675 - Use of iex-1 for the treatment of glioma tumors: The present invention relates to a nucleic acid molecule encoding for IEX-1 polypeptide as a medicament. In a further aspect the present invention relates to a nucleic acid molecule encoding for IEX-1 polypeptide for the manufacture of a medicament for the treatment of gliomas.... Agent: Fulbright & Jaworski L.L.P.

20090221680 - Aptamers that bind thrombin with high affinity: The invention provides aptamers capable of binding to thrombin useful as therapeutics for and diagnostics of coagulation related disorders and/or other diseases or disorders in which thrombin has been implicated. The invention further provides materials and methods for the administration of aptamers capable of binding to thrombin.... Agent: Robins & Pasternak

20090221683 - Combination of cxcr4 antagonist and morphogen to increase angiogenesis: The present invention generally provides methods for preventing, treating or reducing the severity of symptoms associated with tissue ischemia by administering a CXCR4 antagonist in combination with at least one nucleic acid encoding a morphogen or effective fragment thereof. In one embodiment, the methods include elevating peripheral blood endothelial progenitor... Agent: Edwards Angell Palmer & Dodge LLP

20090221682 - Dna vaccine for cancer therapy: The invention relates to a fusion gene useful as a therapeutic and prophylactic vaccine against cancer. The fusion gene contains a DNA encoding ubiquitin gene fused to a second DNA encoding growth factor receptors or fragment thereof, over expressed in various types of cancer. In particular, the invention is illustrated... Agent: Schwegman, Lundberg & Woessner, P.A.

20090221686 - Modulation of the transcription of pro-inflammatory gene products: The present invention refers to inhibitors of the transcription factors IRF-1, their use as therapeutic agents as well as their use for prevention and therapy of cardiovascular complications like re-stenosis after percutaneous angioplasty or stenosis of venous bypasses, chronic (transplant arteriosclerosis or vasculopathy) or acute transplant rejection, graft versus host... Agent: Fulbright & Jaworski L.L.P.

20090221684 - Molecules for gene delivery and gene therapy, and methods of use thereof: One aspect of the present invention relates to a synthetic non-viral vector composition for gene therapy. Another aspect of the invention relates to the use of the composition for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention also encompasses a pharmaceutical composition (useful for delivery... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090221679 - Novel hiv targets: Using a method to measure the effect of downregulation of certain cellular proteins on HIV integration, host proteins implicated in HIV infection were identified. The identified proteins and encoding nucleic acids provide targets for inhibiting HIV infection and for evaluating the ability of compounds to inhibit HIV infection. Compounds inhibiting... Agent: Merck And Co., Inc

20090221681 - Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer: A nucleic acid construct that includes (i) a first nucleic acid sequence encoding TNF alpha; (ii) a second nucleic acid sequence encoding a Diphtheria toxin; and (iii) at least one additional nucleic acid sequence of a cancer specific promoter. The TNF alpha and Diphtheria toxin encoding sequences are under an... Agent: Winston & Strawn LLP Patent Department

20090221685 - Oligomeric compounds and compositions for the use in modulation of micrornas: Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA... Agent: Woodcock Washburn LLP

20090221521 - Systemic purine administration: modulating axonal outgrowth of central nervous system neurons: Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic... Agent: Rissman Hendricks & Oliverio, LLP

20090221522 - Methods to correct gene set expression profiles to drug sensitivity: The present invention comprises a treatment approach based on gene set-expression signatures that systematically connects a sample to a profile from a reference database to extrapolate the most effective therapeutic agent. Further disclosed are methods to optimize combination treatments.... Agent: Banner & Witcoff, Ltd.

20090221523 - North-2'-deoxy-methanocarbathymidines as antiviral agents against poxviruses: A method for the prevention or treatment of poxvirus infection by administering an effective amount of an antiviral agent comprising cyclopropanated carbocyclic 2′-deoxynucleoside to an individual in need thereof is provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090221524 - Odcase inhibitors for the treatment of malaria: The present invention includes methods of treating or preventing malaria by administering an anti-malarial effective amount of 6-substituted uridine derivatives to a subject need thereof. The invention also includes new 6-substituted uridine derivatives for use as therapeutics, in particular to treat malaria.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090221525 - Functional foods against tumors: The present invention relates to the technical field of functional foods, more precisely novel functional foods for the treatment and/or prevention of malignant carcinomas of the human or animal body, and also to processes for producing such functional foods.... Agent: Ostrolenk Faber Gerb & Soffen

20090221526 - Ngna compositions and methods of use: The present invention relates to the field of viral disorders, and in particular to viral obesity. Compositions comprising nutraceutical agents are provided for treating viral obesity. Additionally, compositions comprising nutraceutical agents targeting adenoviruses are provided.... Agent: Casimir Jones, S.c.

20090221527 - Tumor necrosis factor inhibitors: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions.... Agent: Woodcock Washburn LLP

20090221528 - Therapeutic micro nutrient composition for lipolysis and sclerosis: An improved formulation and method for the removal of subcutaneous fat deposits in a human in need of such treatment. It also induces an inflammatory reaction which treats disorders of tissue adhesion which often accompany subcutaneous fat deposits or are created in the process of removal of subcutaneous fat deposits.... Agent: James Robert Deluze

20090221529 - Heterocycles and derivatives thereof and methods of manufacture and therapeutic use: This invention relates to the design, synthesis and use of synthetic vitamin D and other steroidal analogs. It further relates to the therapeutic use of such analogs and their manufacture.... Agent: Seyfarth Shaw LLP

20090221530 - Relaxase modulators and methods of using same: Methods of treating a microbial infection in a subject by administering to the subject an effective amount of a compound that modulates an enzymatic activity of a relaxase polypeptide is provided. Methods of inhibiting bacterial conjugation by modulating activity of a relaxase polypeptide in a bacterium are also provided. Novel... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090221475 - Treatment of lung disorders: The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III by inhalation.... Agent: Gtc Biotherapeutics, Inc. C/o Wolf, Greenfield & Sacks, P.C.

20090221531 - Novel phytic citrate compounds and process for preparing the same: wherein said R is H or citrate and wherein at least one R is citrate. The salt of the chemical compound is the Na+, K+, Mg2+, or Ca2+ salt of said chemical compound. The chemical compound is a chelator which chelates sodium, potassium or lithium, magnesium, calcium, copper, iron, lead,... Agent: Bingham Mccutchen LLP

20090221532 - Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation: A dosage of a propofol prodrug needed for inducing mild to moderate sedation levels in a patient is calculated based on a patient's lean body mass. It has been discovered dosages based on gross body mass may result in overdosing, particularly for obese patients. In another aspect, a dosage suitable... Agent: Banner & Witcoff, Ltd.

20090221533 - Method of treating fatty liver disease: The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with... Agent: David S. Resnick

20090221534 - Cox2 inhibitor: The present invention relates to an agent having COX-2 inhibition activity. In particular the present invention relates to a COX-2 inhibitor separated from a mixture of denatured plasma and at least one metal, metal ion or metal salt thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20090221535 - Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae: The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, T, U, V, W, X, Y, Z. R4, R5a?, R5b, R5c, R6, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or... Agent: Merck And Co., Inc

20090221536 - Transdermal delivery of beneficial substances effected by a hostile biophysical environment: The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may... Agent: Wolf Greenfield & Sacks, P.C.

20090221537 - Use of 25-hydroxy vitamin d3 to improve vitality of animals: The present invention relates to the use of 25-hydroxy-vitamin D3 to improve the general health status of female animals at least during gestation and/or lactation. The invention also relates to the use of 25-hydroxy-vitamin D3 in animal breeding. More particular, the invention relates to the use of 25-hydroxy-vitamin D3 for... Agent: Nixon & Vanderhye, PC

20090221538 - Methods of treating multiple sclerosis by administering pulse dose calcitriol: Prophylactic or therapeutic treatment to inhibit the development or progress of multiple sclerosis symptoms is provided by providing intermittently administered elevated doses of calcitriol, sufficiently infrequently to avoid hypercalcemia. Such methods may include maintaining at least about a normal blood level of vitamin D3 as evidenced by a 25-(OH)D3 level... Agent: Wisconsin Alumni Research Foundation (warf)

20090221539 - Method of detecting and reducing boar taint using nuclear receptors: A method for preventing or reducing boar taint, a method of screening pigs to determine those more likely to have reduced boar taint and a method for screening substances that enhance skatole metabolism or androstenone in a pig, are disclosed These methods involve the use of the nuclear receptors constitutive... Agent: Mckee, Voorhees & Sease, P.L.C

20090221540 - Method of treating an acute vascular disorder: The invention relates to a method of treating an acute vascular disorder in a mammal. The method comprises orally administering to the mammal an effective amount of a steroid. The steroid is selected from the group consisting of: substances represented by formula (I), in which R1, R2, R3, R4 independently... Agent: The Webb Law Firm, P.C.

20090221541 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous carrier including a thixotropic composition including microcrystalline cellulose and a polymer selected from an alkali metal carboxyalkylcellulose, a polyvinylpyrrolidone polymer, and mixtures... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090221542 - Inhibition of inflammatory cytokine production with tanshinones: Provided are methods of attenuating release of a proinflammatory cytokine from a mammalian cell. Also provided are methods of inhibiting or treating an inflammatory cytokine cascade in a mammal. Further provided are methods of treating a mammal at risk for or undergoing sepsis, septicemia, and/or endotoxic shock. Additionally provided are... Agent: Amster, Rothstein & Ebenstein LLP

20090221543 - New corticosteroids: o

20090221544 - Methods for the treatment of a traumatic central nervous system injury via a tapered administration protocol: The present invention provides methods for the treatment or the prevention of neuronal damage in the CNS. Specifically, the methods of the invention provide for the administration of a therapeutically effective amount of a progestin or progestin metabolite following a traumatic or ischemic injury to the CNS such that, prior... Agent: Foley And Lardner LLP Suite 500

20090221545 - Ophthalmic pharmaceutical composition containing amphiphilic polyaspartamide copolymers: The present invention relates in general to the use of amphiphilic graft-type copolymers of polyaspartamide for the ophthalmic administration of drugs, such as for example steroidal and non-steroidal anti-inflammatory agents, antimicrobial agents such as aminoglycosides, macrolides, cephalosporin, tetracycline, quinolones, penicillin, beta-lactams, anti-glaucoma agents such as prostaglandins, alpha- and beta-blockers, inhibitors... Agent: Shoemaker And Mattare, Ltd

20090221546 - Inhibitors of factor xa and other serine proteases involved in the coagulation cascade: e

20090221547 - Immunosuppressant compounds and compositions: The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction. This application... Agent: Genomics Institute Of The Novartis Research Foundation

20090221548 - Melanin concentrating hormone receptor-1 antagonists: Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or... Agent: Louis J. Wille Bristol-myers Squibb Company

20090221549 - Antihypertensive therapy: A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is... Agent: Harness, Dickey, & Pierce, P.l.c

20090221550 - Compositions for treatment of systemic mastocytosis: The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor... Agent: Novartis Corporate Intellectual Property

20090221551 - Substituted fused[1,2] imidazo[4,5c] ring compounds and methods: [1,2]Imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) substituted with a fused ring containing an oxygen and/or nitrogen atom attached at the 1- and/or 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in... Agent: Pfizer Inc. Patent Department

20090221552 - Methods for the treatment of adhd and related disorders: The invention features methods, compositions, and kits for the treatment of attention deficit hyperactivity disorder and related behavioral disorders by administering an organic cation 3 (hOCT3) inhibitor.... Agent: Clark & Elbing LLP

20090221553 - Methods for treatment of sexual dysfunction: This invention is directed to a method of treating sexual dysfunction in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower... Agent: Gibbons P.C.

20090221554 - Method of treating cognitive impairment: Disclosed is an method of treating cognitive impairment, including administering to a subject in need thereof a combination of a therapeutic agent for neurodegenerative disease and a therapeutically effective amount of a heterocyclic compound represented by the following general formula (I):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090221555 - Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be... Agent: Ross J. Oehler Cephalon, Inc.

20090221557 - 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to,... Agent: Brinks Hofer Gilson & Lione

20090221556 - Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods: 1H-Imidazo[4,5-c]quinolin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are... Agent: Pfizer Inc. Patent Department

20090221558 - Methods of modulating the activity of the mc5 receptor and treatment of conditions related to this receptor: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to,... Agent: Brinks Hofer Gilson & Lione

20090221559 - Benzodiazepines as hcv inhibitors: The present invention relates to the use of benzodiazepines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to benzodiazepine compounds per se and their use as medicines. The present invention also concerns... Agent: Philip S. Johnson Johnson & Johnson

20090221560 - Pharmaceutical formulation: This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, one or more suitable pharmaceutical excipients and a compound of formula (I) and/or a compound of formula (II): or a pharmaceutically acceptable salt thereof.... Agent: Buckley, Maschoff & Talwalkar LLC

20090221561 - Cell migration modulating compounds: The described invention relates to compounds which modulate cell migration, and find use in, for example, wound healing, cancer progression and angiogenesis.... Agent: Myers Bigel Sibley & Sajovec

20090221562 - Novel opioid antagonists: Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.... Agent: Feldmangale, P.A.

20090221563 - Oral suspension comprising meloxicam: The present invention relates to an oral suspension comprising meloxicam, its preparation and its use in alleviating inflammation and pain in both acute and chronic musculo-skeletal disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090221564 - Heterocyclic compounds and their use in the treatment of cardiovascular disease: Heterocyclic compounds of the formula (I) are provided: wherein ring A, ring B, R1, R2, R3, R4, Y, m, n and q are as identified herein. R1 is in particular amidino. The invention further provides particular benzothiophene compounds. Compounds of the invention may be useful as inhibitors of Factor IXa... Agent: Klarquist Sparkman, LLP

20090221565 - Novel 7-substituted 3-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials: t

20090221566 - Inhibitors of phosphodiesterase type-iv: The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090221567 - Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177: e

20090221568 - Synthesis of inhibitors of ftsz: FtsZ, the bacterial analog of tubulin, is a promising new target for developing new antibiotics. It has been shown that polyphenols inhibit the GTPase activity of FtsZ, thereby inhibiting Z-ring formation during mitosis. The present invention provides novel polyphenols compounds, which can be accessed by the synthesis of dichamametin and... Agent: Choate, Hall & Stewart/harvard University

20090221569 - Use of lhrh antagonists for intermittent treatments: The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonistsuch that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090221571 - Hiv integrase inhibitors: wherein R1, R2, R3, R4, R5 and R6 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in... Agent: Merck And Co., Inc

20090221570 - Uses of 2-phenyl-substituted imidazotriazinone derivatives for treating pulmonary hypertension: The present invention relates to the use of PDE 5 inhibitors generally and in particular of known 2-phenyl-substituted imidazotriazinone derivatives for manufacturing medicaments for the treatment of pathological states which can be treated by raising cGMP levels in certain tissues, such as, for example, of, for example: primary pulmonary hypertension,... Agent: Barbara A. Shimei Director, Patents & Licensing

20090221572 - 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands: The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some 4, 5, 6, 7 tetrahydrobenzo[b]thiophene derivatives, wherein n is selected from 0, 1, 2, 3 or 4; m is selected from 0, 1 or 2; the dotted line represents either a... Agent: Heslin Rothenberg Farley & Mesiti PC

20090221573 - Use of activators of soluble guanylate cyclase for promoting wound healing: The present invention relates to a method for promoting wound healing by administering one or more compounds identified in the claims, and to pharmaceutical compositions containing such compounds.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090221574 - 5-lipoxygenase-activating protein (flap) inhibitors: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090221576 - Pharmaceutical use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl) pyridin-2-yl]-1h-in-dole-5-carbonitrile as a free base or salts: New use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof, in a method of prevention and/or treatment of bone-related disorders, osteoporosis, increasing bone formation or increasing bone mineral density.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090221575 - Sulfonamide derivatives and use thereof for the modulation of metalloproteinases: w

20090221577 - Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors:

20090221578 - Organic compounds:

20090221584 - Bisaryl-sulfonamides: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ or PPARδ. In particular, the compounds of the invention modulate the function of PPARγ or PPARδ. The subject methods are particularly useful in the treatment and/or prevention of... Agent: Jones Day

20090221581 - Methods of treating pain: The invention relates to methods of treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.... Agent: Olson & Cepuritis, Ltd.

20090221583 - Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090221582 - Piperazine derivatives and their use in therapy: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors wherein R1 is a radical of formula -(Alk1)m-(NH)p-(Alk2)n-Q wherein m, n and p are independently 0 or 1, Alk1 and Alk2 are straight or branched chain divalent C1-C6 alkylene or... Agent: Banner & Witcoff, Ltd.

20090221579 - Substituted amino-compounds and uses thereof: This invention relates to novel compounds having the structural formula Ia or formula Ib: Ia Ib and their pharmaceutically acceptable salts, tautomers or in vivo hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of Aβ related pathologies such as cognitive impairment, Alzheimer... Agent: Pepper Hamilton LLP

20090221580 - Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase: This invention comprises the novel compounds of formula (I) wherein R1, R2, R3, R4, X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.... Agent: Philip S. Johnson Johnson & Johnson

20090221585 - Novel compounds and their use related to compositions for treating disease: Novel compounds and their uses are disclosed herein.... Agent: Allergan, Inc.

20090221586 - Oxazole compound and pharmaceutical composition: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(═O)— wherein Y1 is a group such... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090221587 - Novel insecticides: Compounds of formula (I), wherein the substituents are as defined in claim (1), and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090221588 - Fungicidal compositions: A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of Formula (I) or a compound of Formula (II) wherein R1b is difluoromethyl or trifluoromethyl and R2b is alkyl, alkoxyalkyl or haloalkyl, or tautomers of such compounds; and (B) a compound selected from compounds known for... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090221590 - Salt of cd 80 antagonist: The choline salt of the CD80 antagonist compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide (I) has good aqueous solubility and is therefore convenient for pharmaceutical use.... Agent: Banner & Witcoff, Ltd.

20090221589 - Use of aminoalcohol derivatives for the treatment of overactive bladder: The present invention relates to the use of new beta-agonists of general formula (Ia) or (Ib) wherein the groups R1 to R12 and R1 to R7, respectively, have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090221595 - Crystalline form of sitagliptin: A Sitagliptin crystalline form characterized by PXRD pattern having any 5 peaks selected from the group consisting of 7.4, 11.5, 16.7, 17.7, 18.9, 24.1, 24.5, 27.0, 28.5 and 28.8±0.2 degrees 2-theta, wherein any combination of peaks selected includes the peak at 7.4±0.2 degrees two theta, processes for preparing said Sitagliptin... Agent: Kenyon & Kenyon LLP

20090221592 - Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor: The dodecylsulfate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the treatment of Type 2 diabetes. The invention also relates to a crystalline anhydrate of the dodecylsulfate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods... Agent: Merck And Co., Inc

20090221591 - Selective inhibitors of human corticosteroid synthases: The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090221594 - Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolate: The invention provides a stable lyophilized composition of 5,10 methylenetetrahydrofolate suitable for use in the treatment of cancer and other therapies. The composition comprises 5,10-MTHF in combination with citric acid and ascorbic acid, with the ratio of citric acid to ascorbic acid from about 0.75:1 to about 2.25:1 by weight,... Agent: Townsend And Townsend And Crew, LLP

20090221593 - Triazole derivatives as modulators of dopamine d3 receptors: e

20090221597 - Heteroaryl derivatives as cftr modulators: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20090221598 - Use of sanglifehrin in hcv: The present invention discloses the use of a cyclophilin-binding compound such as a sanglifehrin for the treatment and prevention of hepatitis C and related diseases such as liver fibrosis, liver cirrhosis and hepatocellular carcinoma.... Agent: Novartis Corporate Intellectual Property

20090221599 - Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents: e

20090221596 - Substtituted aryl oximes:

20090221600 - Pyrido-pyridimidine derivatives useful as antiinflammatory agents: Provided are novel pyrido-pyrimidine derivatives, having the structure of Formula (I): which can be used as anti-inflammatory agents. Also provided are pharmaceutical compositions comprising one or more pyrido-pyrimidine derivatives, as well as methods of treating autoimmune diseases, inflammation or associated pathologies, including for example, sepsis, rheumatoid arthritis, inflammatory bowel disease,... Agent: Ranbaxy Inc.

20090221601 - Methods of identifying and treating individuals exhibiting mutant kit protein: The invention described herein relates to methods of identifying and treating individuals with protein tyrosine kinase associated disorders that have, or may, become resistant to treatment with a kinase inhibitor such as imatinib due to a gain-of-function mutation in KIT tyrosine kinase.... Agent: Ropes & Gray LLP

20090221602 - Processes for preparing substituted pyrimidines: The present invention provides a facile process for the preparation of tri- and tetra-substituted pyrimidines. The process is useful for preparing inhibitors of protein kinases, especially Aurora kinase. These inhibitors are useful for treating or lessening the severity of Aurora-mediated diseases or conditions.... Agent: Vertex Pharmaceuticals Inc.

20090221603 - Heterocyclic amide derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (1) where Z is N or ═CHNR2 and X is NR2, O, S, S═O or... Agent: Morrison & Foerster LLP

20090221604 - Thiazole compounds and their use as pgd2 antagonists: A compound for use as a PGD2 antagonist is of structural formula [1] in which: A represents a fully saturated or partially unsaturated monocyclic 5-7 membered ring containing one or two nitrogen atoms; B represents a direct bond, an optionally substituted methylene group, an optionally substituted nitrogen atom, oxygen, or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090221606 - Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-ylimethanone phosphate: The present invention relates to novel crystalline forms of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate and to pharmaceutical compositions containing said forms.... Agent: Millen, White, Zelano & Branigan, P.C.

20090221605 - Substituted pyrrole-2, 5-diones as protein kinase c inhibitors: e

20090221607 - Piperazine derivatives:

20090221609 - Gene predictors of response to metastatic colorectal chemotherapy: The present invention provides for the identification of genes that are expressed in tumors that are responsive to a given therapeutic regime and whose expression correlates with responsiveness to that therapeutic regime. One or more of the genes of the present invention can be used as markers to identify patients... Agent: Foley And Lardner LLP Suite 500

20090221608 - Pyrazole compounds: e

20090221610 - Compositions and methods for treating cognitive disorders: The present invention relates to the use of inhibitors or blockers of Ih (hyperpolarization-activated cationic current) channels in the treatment of cognitive disorders. In preferred aspects of the present invention, an effective amount of a compound is administered to a patient in need, wherein the compound has the chemical structure:... Agent: Coleman Sudol Sapone, P.C.

20090221611 - Fused triazole tachykinin receptor antagonists: The present invention is directed to certain fused triazole compounds which are useful as neurokinin-1 (NK-I) receptor antagonists, and inhibitors of tachykinin and in particular substance P- The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations... Agent: Merck And Co., Inc

20090221612 - Certain substituted amides, method of making, and method of use thereof: Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090221613 - Use of adenine-derived compounds for the treatment of lupus: The invention relates to the use of adenine-derived compounds substituted in the 2- and 9-positions and, optionally, in the N(6)-position of the adenine, for the manufacture of a medicament for use in the treatment of systemic lupus erythematosus (SLE). The compounds can also be used in combination with a second... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090221615 - Combination anti-cancer agents: The present disclosure relates to methods of treating cancer in mammals by administration of Lucanthone and at least one anti-metabolite. Pharmaceutical compositions and kits comprising Lucanthone and at least one anti-metabolite also are disclosed.... Agent: K&l Gates LLP

20090221614 - Selective serine/threonine kinase inhibitors: Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at... Agent: Townsend And Townsend And Crew, LLP

20090221616 - Quinazoline derivatives as egf and/or erbb2 tyrosine kinase inhibitors: A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.... Agent: Morgan Lewis & Bockius LLP

20090221618 - Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors: q

20090221617 - Lead compound of anti-hypertensive drug and method for screening the same: A system for screening a small molecule library with 250,000 molecules to find out a compound of an anti-hypertensive drug aiming at human Angiotensin II type IA receptor is provided. The system includes a first database having a three-dimensional structure datum of a human Angiotensin II type IA receptor, a... Agent: Trojan Law Offices

20090221620 - Gentic polymorphisms associated with stroke, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with vascular diseases such as stroke. In particular, the present invention relates to genetic polymorphisms that have utility for such uses as predicting disease risk or predicting an individual's response to a treatment such as statins,... Agent: Celera Corporation

20090221619 - Novel materials and methods for the production thereof: The present invention relates to, inter alia, methods for the treatment of wallboards with fungicides and the treated wallboards. In particular, the invention relates to the treatment of wallboards with synergistic combinations of an anilinopyrimidine fungicide and other fungicides. The invention also provides the treatment of building materials with synergistic... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090221621 - Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms: Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with aqueous alcohol.... Agent: Maurice M Klee

20090221622 - Topotecan ready to use solutions: Aqueous-based, ready to use topotecan-containing formulations for parenteral use having extended stability are disclosed. The formulations are surprisingly free of precipitated degradation products such as 10-hydroxycamptothecin (10-HCPT) after periods of up to 1 year or greater.... Agent: Lucas & Mercanti, LLP

20090221623 - Indole alkaloid derivatives having opioid receptor agonistic effect, and therapeutic compositions and methods relating to same: Indole alkaloid derivatives having an opioid receptor agonistic effect, their synthesis, and therapeutic compositions containing these derivatives, and methods of treating conditions with these compounds and therapeutic compositions, are provided.... Agent: Kilyk & Bowersox, P.l.l.c.

20090221624 - 4-aminoquinoline compounds for treating virus-related conditions: This invention is directed to aminoquinoline compounds, pharmaceutical compositions of such compounds, kits comprising such compounds, and uses of such compounds for preparing medicaments and treating virus-related conditions in animals.... Agent: Sonnenschein Nath & Rosenthal LLP

20090221626 - Aerosol formulation for inhalation containing an anticholinergic agent: The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090221625 - Cosmeceutical composition: Topical compositions comprising: —a physiologically acceptable alkanediol, ether diol or diether alcohol containing up to (8) carbon atoms; —water; and—optionally an unsaturated fatty alcohol; and optionally further conventional excipients, for use as a cosmeceutical, in particular for use in the repair or maintenance of skin barrier function. They are indicated... Agent: Gerber Products Company

20090221627 - Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use: Some exemplary embodiments comprise fluoro-containing derivatives of pyrido[4,3-b]indoles (and exemplary methods of making the same) that may be administered to a mammal (including a human) in an effective amount for potential use in the treatment or prophylaxis of neurological disorders including AD, mild cognitive impairment, senile and vascular dementia, HD,... Agent: Carr & Ferrell LLP

20090221628 - Compositions and methods for treatment of prostate and breast cancer: Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast... Agent: Davidson, Davidson & Kappel, LLC

20090221629 - Method for antagonizing mif activity: Methods of antagonizing MIF activity using ibudilast are described. Also described are methods of screening for MIF antagonists. These agents can be used for treating addictions, including drug and behavioral addictions, as well as for treating neuropathic pain.... Agent: Robins & Pasternak LLP

20090221630 - Iap inhibitors: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3, R4, R4, R5, R6, R6′ and n are as described herein.... Agent: Genentech, Inc.

20090221632 - Bicyclo-pyrazoles and pharmaceutical compositions comprising them: Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.... Agent: Scully Scott Murphy & Presser, PC

20090221631 - Imidazopyridinones: c

20090221633 - Inhibitors of akt (protein kinase b): 4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt thereof as Akt inhibitors that are antineoplastic and/or antiviral agents as well as compositions comprising these compounds and methods of using these compounds.... Agent: Eli Lilly & Company

20090221634 - Compositions and methods for disruption of brca2-rad51 interaction: Contemplated compounds disrupt interaction between BRCA2 and RAD51, likely by binding to RAD51. Based on the crucial role of the BRCA2-RAD51 complex formation in DNA repair and the role of RAD51 in the control of entry into S-phase from G1, numerous compositions and methods are presented. Among other advantageous uses,... Agent: Fish & Associates, PC Robert D. Fish

20090221635 - Quinolinyl and benzothiazolyl modulators: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPARγ. In particular, the compounds of the invention modulate the function of PPARγ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid... Agent: Jones Day

20090221636 - Argatroban formulations and methods for making and using same: Formulations comprising argatroban and methods of making and using the formulations are provided. In an embodiment, the formulation comprises a solution having an argatroban concentration ranging from greater than about 10 to about 500 mg/mL. The solution can comprise an aqueous solution. The solution can be packaged in a sealed... Agent: K&l Gates LLP

20090221638 - Crystalline form of a biphenyl compound: The invention provides a crystalline 1,2-ethanedisulfonic acid salt of biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5 -yl)ethylamino]methyl}-5-methoxyphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also provides pharmaceutical compositions comprising such a salt or prepared using such a salt; processes and intermediates for preparing such a salt; and methods of using such a salt to... Agent: Theravance, Inc.

20090221637 - Solid-state salt argatroban formulations and methods for producing and using the same: Argatroban formulations and methods of making and using the formulations are provided. In an embodiment, the present disclosure provides a solid-state salt formulation of argatroban. Upon reconstitution, the solid-state argatroban forms a solution that can be essentially free of particles and suitable for administration. The solid-state argatroban can be in... Agent: K&l Gates LLP

20090221639 - Heterocyclic gpcr agonists: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.... Agent: Osi Pharmaceuticals, Inc.

20090221640 - Novel crystal modifications: Novel crystal modifications of (5S)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione are disclosed together with processes for preparing such modifications, pharmaceutical compositions comprising such a modification, and the use of such a modification in therapy.... Agent: Fish & Richardson P.C.

20090221641 - Diaza-spiro--nonane derivatives as neurokinin (nk1) antagonists: This invention concerns substituted diaza-spiro-[4.4]-nonane derivatives having neurokinin antagonistic activity, in particular NK1 antagonist ic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nocicept ion,... Agent: Woodcock Washburn LLP

20090221642 - Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176: i

20090221643 - 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia: wherein Ar is selected from phenyl, pyridyl and thienyl optionally substituted with one or more groups Y; and each Y group is independently selected from the group consisting of: halo, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, cyano, C(O)C1-4alkyl, NHSO2C1-4alkyl, NMeSO2C1-4alkyl, NHCOC1-4alkyl, NMeCOC1-4alkyl, SOC1-4alkyl, SO2C1-4alkyl and CO2C1-4alkyl, or two Y groups together form a... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090221644 - Gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20090221646 - Crystalline solvate of omeprazole sodium: m

20090221645 - Dihydroimidazothiazole derivatives: Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.... Agent: Osi Pharmaceuticals, Inc.

20090221647 - N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.... Agent: Hoffmann & Baron, LLP

20090221648 - Compositions for treatment of cognitive disorders: The present invention relates to compositions for treatment of cognitive deficits. Such compositions can have a nicotinic acetylcholine receptor ligand, of either α4β2 subtype or α7 nicotinic acetylcholine subtype, and a histamine-3 receptor ligand, a method of using the same, and a related article of manufacture. Combinations of such active... Agent: Paul D. Yasger Abbott Laboratories

20090221649 - Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage: The invention relates to substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines of formula (I) and their use in medicaments for the prophylaxis and/or treatment of reperfusion injury and damage.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090221650 - Use of pyridoxamine to treat and/or prevent disease processes: Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090221651 - Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage: A method of preventing HIV-1 associated dendritic pathology in a brain cell, comprising contacting the cell with a therapeutically effective dose of a mitochondrial ATP-sensitive potassium channel agonist. A method of preventing HIV-1 associated dendritic pathology in a brain cell, comprising contacting the cell with a therapeutically effective dose of... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090221652 - Combinations of metformin and meglitinide: Methods of treating glucose related disorders, for example by administering a meglitinide such as mitiglinide, repaglinide, or nateglinide, optionally in combination with a biguanide such as metformin, are described herein.... Agent: Lando & Anastasi, LLP E2023

20090221653 - 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3h)-one-derivatives as beta2 adrenoreceptor agonists: The present invention provides compounds of formula (I) wherein the variables are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20090221654 - Prostaglandin e1 and e2 analogs for the treatment of various medical conditions: A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction,... Agent: Reising, Ethington, Barnes, Kisselle, P.C.

20090221655 - Antibacterial agents: The present invention provides a compound of Formula (I) Or a pharmaceutically acceptable salt thereof wherein: W is CH2NHC(═Z)R1, C(═Z)NHR2, or CH2het; X is H, C1-6alkyl, or C2-6alkenyl; Y is H, or F; Z is O, or S; R1 is C1-6alkyl, NHC1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, or OC1-4alkyl; R2 is H, C1-4alkyl,... Agent: Pfizer Inc Mary J Hosley

20090221656 - Drug combinations: (ii) at least one compound from the following classes of compounds: diuretics; beta-adrenergic antagonists; alpha2-adrenergic agonists; alpha1-adrenergic antagonists; dual beta- and alpha-adrenergic antagonists; calcium channel blockers; potassium channel activators; anti-arrhythmics; ACE inhibitors; AT1 receptor antagonists; renin inhibitors; lipid lowerers, vasopeptidase inhibitors; nitrates; endothelin antagonists; neutral endopeptidase inhibitors; anti-angiotensin vaccines;... Agent: Conley Rose, P.C.

20090221657 - Compounds, compositions containing them, preparation thereof and uses thereof i: i

20090221658 - Pharmacological treatment for sleep apnea: The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity.... Agent: Marshall, Gerstein & Borun LLP

20090221659 - Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea: An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of siaiorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090221660 - Novel crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid 471: New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.... Agent: Morgan Lewis & Bockius LLP

20090221661 - Phosphodiesterase 4 inhibitors: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.... Agent: Millen, White, Zelano & Branigan, P.C.

20090221662 - Method for controlling arthropods: The present invention relates to a method for controlling arthropods by indirect contact action using the pesticides mentioned in the description.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090221663 - Pyrazole derivatives as 11-beta-hsd1 inhibitors: e

20090221664 - Pharmaceutical compositions of muscarinic receptor antagonists: Provided herein are pharmaceutical compositions comprising one or more muscarinic receptor antagonists (“MRA”), and at least one additional active ingredients selected from one or more β2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or a mixture thereof and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition,... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090221665 - Organic compounds: The present invention relates to a combination of a 5-HT4 receptor agonist and a cholinesterase inhibitor and pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination may be employed for the treatment of altered gastrointestinal motility, sensitivity, secretion or abdominal disorders. The dosage is preferably oral. The preferred 5-HT4... Agent: Novartis Corporate Intellectual Property

20090221666 - Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth: The present invention provides stilbene derived compounds having antineoplastic and/or antimicrobial activity. Preferred compounds of the invention include compounds of the formula (I) wherein R is Dap, Dap-Dil, Dap-Dil-Val, or Dap-Dil-Val-Dov; R1 is H, OH, or PO3Na2; and R2 and R3 are jointly —CH2— or each independently H, OH, CH3,... Agent: Mcandrews Held & Malloy, Ltd

20090221667 - Process for annealing amorphous atorvastatin: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.... Agent: Pfizer Inc. Patent Department

20090221669 - Disubstituted aniline compounds: The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit hi-stone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention... Agent: Merck And Co., Inc

20090221668 - Synthesis and preparations of duloxetine salts: The invention relates to an improved process for preparing duloxetine hydrochloride. More particularly, the invention relates to the preparation of duloxetine hydrochloride by a process that provides a maximum yield of desired product with a minimum amount of undesired by-products.... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090221687 - Tetracyclic monoamine reuptake inhibitors for treatment of cns diseases and disorders: Novel tetracyclic dibenzo(e,h)azulene compounds of formula I; their pharmacologically acceptable derivatives; process and intermediates for their preparation; pharmaceutical compositions containing them and their activity and use in the treatment of central nervous system (CNS) diseases and conditions in humans and animals.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090221688 - Pharmaceutical compositions containing docetaxel and a degradation inhibitor and a process for obtaining the same: Pharmaceutical compositions containing polysorbate 80, anhydrous docetaxel (I) or its trihydrate and an organic acid with a pKa between 2.5-4.5 employed as a degradation inhibitor.... Agent: Birch Stewart Kolasch & Birch

20090221689 - Macrocyclic modulators of the ghrelin receptor: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin... Agent: Myers Bigel Sibley & Sajovec

20090221690 - Pharmaceutical composition for the prevention/treatment of bone disorders and a process for the preparation thereof: Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no... Agent: Arent Fox LLP

20090221692 - Cb2 receptors blocks accumulation of human hepatic myofibroblasts: a novel antifibrogenic pathway in the liver: Methods for treating diseases of the livers mediated by CB2 receptors are described. The methods may include administering an effective amount of a cannabinoid, an agent that activates a CB2 receptor, a composition that includes a non-selective agonist of CB2 and a selective antagonist of CB1, a composition that includes... Agent: Townsend And Townsend And Crew, LLP

20090221691 - Compositions and methods for inhibiting g protein signaling: The present invention relates to methods for identifying agents which bind to specific amino acid residues of the protein interaction site of G protein β protein subunit. Compounds identified in accordance with the assay of the invention and methods for using the compound for modulating at least one activity of... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090221693 - Novel use of organic compounds: The present invention refers to compounds of the general formulae I as defined above, preferably α-mangostin, for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function and endurance. Other... Agent: Nixon & Vanderhye, PC

20090221695 - Chroman derivatives as estrogenic compounds: wherein R1 is (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl, and independently R1 has a cis-orientation in relation to the exocyclic phenyl group at the 2-position of the skeleton; R4 is H, Hal, CF3, OH or (1C-2C)alkyloxy; R2, R3, and R5 are independently H, Hal, CF3, (1C-4C)alkyl, (2C-4C)alkenyl or (2C-4C)alkynyl and prodrugs thereof... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090221696 - Composition for treating cancer cells and preparation method for the same: A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells.... Agent: Trojan Law Offices

20090221694 - Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone: Compositions comprising epigallocatechin gallate and 4-(4-hydroxyphenyl)-2-butanone may be used for treatment or prevention of obesity or conditions associated with obesity such as non-insulin-dependent diabetes mellitus (NIDDM, type II) and syndrome X. The compositions may find use in the nutritional field as a supplement to food and beverages, as well as... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP

20090221697 - Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase: The present invention relates to macrolide conjugates of pyrrolizine and indolizine derivatives with macrocyclic antibiotics and derivatives thereof. The macrolide conjugates are potent inhibitors of 5-lipoxygenase and cyclooxygenase and are therefore suitable to treat disorders of the rheumatic type and to prevent allergically induced diseases. The macrolide conjugates have significantly... Agent: Edwards Angell Palmer & Dodge LLP

20090221698 - Mannose derivatives for killing tumor cells: A method for treating cancer by killing selected tumor cells such as human breast, non-small cell lung cancer cells, pancreatic cancer cells, osteosarcoma cancer cells, and glioblastoma cells, includes administering to a patient in need of treatment, an effective amount of at least one mannose analog such as 2-DG or... Agent: Darby & Darby P.C.

20090221699 - Fab i inhibitors: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.... Agent: Goodwin Procter LLP Patent Administrator

20090221700 - Carisprodol articles and methods: A method of using carisoprodol comprises informing a user that administration of carisoprodol in the presence of food decreases the Cmax for carisoprodol compared to administration in the absence of food. In one embodiment, informing comprises providing printed labeling instructions. Also included are articles comprising a carisoprodol formulation and prescribing... Agent: Cantor Colburn, LLP

20090221701 - Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure: The use of fibrates, particularly clofibrate, is described for the preparation of a medicament useful in the treatment of congestive heart failure.... Agent: Nixon & Vanderhye, PC

20090221702 - Compounds: The present invention provides the use of a compound of the Formula: (I) wherein R1 is C1-5 alkoxy, OCOC1-3Alkyl, O(CH2)2O(CH2)2O(CH2)2OMe, O(CH2)2O(CH2)2O(CH2)2OH or OH; R2 is H, (CH2)nOH, OCH3, Hal or (II) or (III) R3 is H or (CH2)nOH; and R4 is C1-6 alkyl, optionally substituted by one or more of... Agent: Elmore Patent Law Group, PC

20090221703 - High penetration composition and uses thereof: The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites... Agent: Perkins Coie LLP

20090221704 - Process for the preparation of peroxy acids: The present invention relates to a process for the preparation of a solution comprising a first peroxy acid comprising performic acid and a second peroxy acid, said process comprising forming a carboxylic acid solution comprising a first carboxylic acid comprising formic acid, a second carboxylic acid and hydrogen peroxide, wherein... Agent: Cantor Colburn, LLP

20090221705 - Omega 3: A process for the preparation of a water soluble unsaturated fatty acid salt from a crude composition comprising at least one non-water soluble or sparingly water soluble unsaturated fatty acid or salt thereof, said process comprising: adding to said crude composition in the presence of water at least one amino... Agent: Nixon & Vanderhye, PC

20090221706 - Methods of treating cognitive dysfunction by modulating brain energy metabolism: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090221707 - Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained: The present invention relates to a process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, its components including as active principle a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic base chosen from hydroxyethylpyrrolidine or hydroxyethylpiperidine characterized in that... Agent: Abelman, Frayne & Schwab

20090221708 - Medicinal preparation: Medicine, in particular broad spectrum medicinal preparations. This invention is based on the use of 4-chlorine-2-methyl-phenoxy-acetic acid of formula I, the pharmacologically acceptable derivatives thereof, for example on corresponding alkali metal salts of the acid and the derivatives in the form of pharmaceutical preparations exhibiting immunomodulating, anti-inflammatory and anti-tumoral properties... Agent: Pauley Petersen & Erickson

20090221709 - Methods of modifying taste sensation in an animal using compounds that modulate t1r1/t1r3 or t1r2/t1r3 receptors: Methods of modifying taste sensation in an animal are provided. These methods comprise administrating compounds that modulate T1R1/T1R3 or T1R2/T1R3 receptors.... Agent: Hunton & Williams LLP Intellectual Property Department

20090221710 - Acyclic sulfamide derivatives: The present invention is related to acyclic sulfamide derivatives, useful for the manufacture of a medicament for satiety induction and ingestion control, corporal fat modulation and lipidic metabolism regulation and for the manufacture of a medicament for the treatment or prevention of diabetes and cardiovascular diseases. The acyclic sulfamide derivatives... Agent: King & Spalding

20090221711 - Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's... Agent: Howson & Howson LLP / Wyeth

20090221712 - Mandelic hydrazides: Novel mandelic hydrazides of the formula (I), in which R1-R11 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in... Agent: Millen, White, Zelano & Branigan, P.C.

20090221713 - Apoe mimetic agents: The invention provides low molecular weight apoE mimetic agents suitable for preparing a medicament to treat autoimmune, inflammatory or neurodegenerative disease, (X)a-L-(X)b(Formula (I)) wherein each X is a (potentially different) chemical moiety bearing a positive charge at physiological pH a and b are, independently, numbers between 3 and 6; and... Agent: Schwegman, Lundberg & Woessner, P.A.

20090221714 - Pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder using sodium phenylbutyrate: Provided is a pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder, comprising sodium phenylbutyrate (PBA). The pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder in accordance with the present invention provides effects capable of inhibiting increases in locomotor... Agent: Gibbons P.C.

20090221715 - Novel polymorph of atovaquone: The present invention relates to a novel polymorphic form of atovaquone. More particularly, it relates to a novel crystalline form, that has improved solubility and other bulk characteristics suitable for pharmaceutical application. The present invention also relates to processes for preparing a new polymorphic form of atovaquone and its use... Agent: Blank Rome LLP

20090221716 - Composition comprising at least 3 different diols: The present invention relates to a composition comprising at least 3 different diols, wherein said diols have the general structure (CH2)nH2O2, wherein n is the number of CH2 and being between 3 to 10, in a total amount of from about 0.1 to about 50% (v/v), a method for producing... Agent: Merchant & Gould PC

20090221717 - Magnesium ammonium phosphate cement composition: This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090221718 - Metadherin polypeptides, encoding nucleic acids and methods of use: Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of... Agent: Knobbe Martens Olson & Bear LLP

20090221719 - Base material for producing food and fodder: The invention relates to a material consisting of a powder selected from a thickening means and lecithin powder, and syrup. Said material is especially suitable for producing food and fodder. The invention also relates to a method for producing said material, to the use of said material, and to products... Agent: Norris, Mclaughlin & Marcus, Pa

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 5.2742 seconds

PATENT INFO